roche finance report fhoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom finance brief key result sale cer growth core operate profit margin sale pharmaceutical diagnostic group change sales mchf mchf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant currency average rate year end december concept previously label local currency group core result core ep earning share exclude noncore item global restructuring charge amortisation impairment intangible asset allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give therefinance brief roche roche group post solid overall result challenge market core operating profit grow fast sale core earning share increase constant exchange rate cer appreciation swiss franc major currency significant impact result express swiss franc underlie currency exposure mitigate large majority cost base locate outside switzerland sale group sale increase slightly cer billion swiss franc report exchange rate exclude tamiflu group sale grow cer pharmaceutical sale growth exclude tamiflu cer strong growth key oncology product lucentis ophthalmology actemraroactemra rheumatoid arthritis largely offset impact healthcare reform european austerity measure price cut japan low avastin sale western europe diagnostic sale grow cer significantly ahead market professional diagnostic tissue diagnostic major contributor operate result core operating profit increase cer billion swiss franc report exchange rate cost saving operational excellence programme initiated offset substantially low profit contribution avastin tamiflu impact healthcare reform price pressure patent expiry research development expenditure decline cer billion swiss franc core basis primarily drive project prioritisation saving operational excellence cost group sale ifrs operating result include restructure charge operational excellence programme billion swiss franc nonoperate result core net financial expense decrease million swiss franc primarily low interest expense result continued repayment debt take finance genentech transaction net income ifrs net income increase cer billion swiss franc report exchange rate primarily drive strong operating result low restructuring charge low interest expense low tax rate core earning share increase constant currency report exchange rate cash flow operate free cash flow billion swiss franc cer free cash flow billion swiss franc cer repayment debt ahead schedule note bond issue finance genentech transaction repay end financial position net working capital increase reflect high level trade receivable public sector customer certain southern european country net debt position improve billion swiss franc billion swiss franc credit rating position strong moodys upgrade second half standard poor shareholder return dividend propose increase represent consecutive year dividend growth result increase payout ratio subject agm approval total shareholder return tsr increase represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement summary significant accounting policy ccount receivable perating segment information current asset hugai arketable security financial income financing cost cash cash equivalent ncome taxis ccount payable usiness combination accrue current liability global restructuring plan derivative financial instrument mployee benefit provision contingent liability pension postemployment noncurrent liability benefit ebt employee stock option equity equity attributable roche shareholder compensation plan earning share nonvoting equity property plant equipment security oodwill oncontrolle interest ntangible asset statement cash flow ssociate isk management financial longterm asset elated party nventorie subsidiary associate report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche hol ding ltd basel financial statement note financial statement appropriation available earning report statutory auditor financial statement financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group net income increase constant exchange rate drive solid operating performance pharmaceutical diagnostic business cost restructure financing cost tax rate low cost saving operational excellence programme initiate offset substantially low profit contribution reduce sale tamiflu avastin impact healthcare reform price pressure patent expiry strengthen swiss franc major currency average yeartodate basis significant negative impact result express swiss franc underlie currency translation exposure arise nonswiss franc revenue mitigate majority group cost base locate outside switzerland group net income increase constant exchange rate increase translate consolidation swiss franc core eps exclude noncore item global restructuring charge amortisation impairment intangible asset increase constant exchange rate decrease translate swiss franc roche group financial review roche finance report income statement change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest dilute eps chf core result sale royalty operate income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest core eps chf roche finance report roche group financial reviewsale sale increase slightly constant currency swiss franc dollar billion swiss franc exclude tamiflu sale increase constant currency pharmaceutical division represent group sale diagnostic division contribute sale pharmaceutical division stable constant currency billion swiss franc exclude tamiflu increase demand oncology drug herceptin mabtherarituxan xeloda tarceva continue grow strongly additional major growth driver lucentis ophthalmology actemraroactemra rheumatoid arthritis mircera renal anemia positive factor offset expect decline sale tamiflu avastin patent expiry effect neorecormonepogin bonvivaboniva cellcept continue negative impact healthcare reform european austerity measure price cut japan diagnostic division sale billion swiss franc grow constant currency swiss franc dollar strengthen lead market position major growth area professional diagnostic tissue diagnostic divisional operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase core operating result core basis group operating profit increase constant exchange rate decrease swiss franc sale increase cer core operating profit margin division increase increase profitability drive operational excellence programme resource prioritisation particularly market distribution research development operational excellence programme lead decline marketing distribution expense research development cost constant currency strong swiss franc negative effect margin development percentage point group level percentage point pharmaceutical division percentage point diagnostic division roche group financial review roche finance report pharmaceutical division increase core operate profit constant currency drive growth underlie business resource prioritisation operational excellence cost saving efficiency improvement general administration cost offset million swiss franc expense new brand pharmaceutical product fee healthcare reform core operate profit growth diagnostic division constant currency mainly result sale growth productivity improvement programme increase general administration cost corporate shift certain finance function pharmaceutical division corporate operational excellence november group announce details operational excellence programme cost recognise billion swiss franc mainly relate site closure disposal cost pharmaceutical business site closure disposal cost total million swiss franc primarily divestment site palo alto california boulder colorado madison wisconsin kulmbach germany half group announce divest chemical production facility florence south carolina give unfavourable market chemical production asset group expect future capacity requirement small molecule pharmaceutical division account million swiss franc cost million swiss franc relate diagnostic division east japan earthquake earthquake march damage chugai production plant utsunomiya production temporarily halted fully resume end august chugais contract manufacturer affect earthquake result product shipment control last end october chugais promotional activity japan affect event cancel sale employee divert ensure continued product supply information flow customer factor certain negative impact chugais sale profit second half total cost incur writeoff property plant equipment inventory chugai million swiss franc net amount receive insurance earthquake result temporary interruption supply instrument hitachi key supplier roche professional diagnostic business treasury taxation financial income billion swiss franc increase constant exchange rate mainly foreign currency devaluation effect venezuela financing cost billion swiss franc decrease billion swiss franc interest cost low cer debt repay tax expense increase billion swiss franc group effective core tax rate decrease compare mainly low tax rate basel switzerland relatively low percentage profit contribution highertax jurisdiction net income earning share net income increase constant exchange rate drive solid operating performance low financing cost low tax rate overall low noncore item global restructuring charge genentech integration low charge operational excellence initiative core basis net income high increase dilute eps cer increase net income describe core eps exclude noncore item global restructuring charge amortisation impairment intangible asset increase constant exchange rate decrease swiss franc supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result roche finance report roche group financial reviewfinancial position change change mchf mchf chf cer pharmaceuticals net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset half swiss franc strengthen currency follow intervention swiss central bank trend reverse second half overall currency translation effect largely net balance sheet carry value consolidate swiss franc pharmaceutical division net work capital decrease constant currency despite increase trade receivables public sector customer southern european country particularly spain portugal continue sale growth china longterm net operating asset decrease constant currency utilisation provision create operational excellence restructure programme offset low property plant equipment follow site disposal diagnostic increase net work capital constant currency drive buildup trade receivable certain southern european country increase inventory level product launch buildup hitachi source instrument earthquake japan longterm net operating asset constant currency increase creation provision partially offset high level property plant equipment improvement net debt position mainly free cash flow billion swiss franc describe pension increase net pension liability reflect fall interest rate lead discount define benefit obligation high free cash flow change change mchf mchf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay dividend pay free cash flow group operate free cash flow remain strongly positive billion swiss franc increase constant currency swiss franc drive strong operating result partly offset increase net work capital proceed site divestment low capital expenditure contribute growth operate free cash flow free cash flow decrease billion swiss franc billion swiss franc primarily lower free cash flow swiss franc term high dividend payment roche group financial review roche finance report pharmaceutical division operating result pharmaceutical division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core eps roche finance report roche group financial reviewsale overview pharmaceutical division sale therapeutic area change sale sale therapeutic area mchf mchf cer oncology inflammationautoimmunetransplantation virology metabolismbone ophthalmology respiratory disease renal anemia cardiovascular disease central nervous system infectious disease therapeutic area total sale pharmaceutical division sale stable constant currency growth key product offset negative impact healthcare reform austerity measure pricing pressure expect decrease sale certain major medicine exclude tamiflu sale growth pharmaceutical division constant currency primarily drive product herceptin mabtherarituxan lucentis actemraroactemra mircera product represent portfolio generate billion swiss franc additional sale growth partly offset low sale tamiflu avastin neorecormonepogin bonvivaboniva cellcept healthcare reform european austerity measure base effect japanese biennial price cut implement april combine incremental negative impact million swiss franc compare equivalent percentage point divisional sale growth oncology continue account majority division sale continue growth herceptin mabthera rituxan offset expect decline avastin sale virology sale tamiflu continue decrease substantially overall pegasys sale decline year begin recover second half follow launch new hepatitis medicine combination pegasys sale inflammationautoimmunetransplantation increase constant currency strong uptake actemraroactemra growth mabtherarituxan rheumatoid arthritis compensating negative impact continue generic erosion cellcept roche group financial review roche finance report product sale pharmaceutical division sale change sale sale mchf mchf cer oncology avastin herceptin mabtherarituxan xeloda tarceva neutrogin neorecormonepogin total oncology inflammationautoimmunetransplantation cellcept mabtherarituxan actemraroactemra total inflammationautoimmune transplantation virology pegasys valcytecymevene tamiflu copegus total virology metabolismbone bonvivaboniva nutropin xenical evista total metabolismbone ophthalmology lucentis total ophthalmology respiratory disease xolair pulmozyme total respiratory disease renal anemia neorecormonepogin mircera total renal anemia roche finance report roche group financial reviewpharmaceutical division sale continue change sale sale mchf mchf cer cardiovascular disease activasetnkase total cardiovascular disease central nervous system madopar rivotril total central nervous system infectious disease rocephin total infectious disease therapeutic area total sale total mabtherarituxan sale million swiss franc million swiss franc split oncology inflammationautoimmune transplantation franchise total neorecormonepogin sale million swiss franc million swiss franc split renal anemia oncology franchise mabtherarituxan change sale sale mchf mchf cer united states western europe japan international total sale mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ancaassociate vasculitis sustain growth oncology segment drive continue strong uptake new firstline maintenance indication follicular lymphoma type nhl europe uptake cll sale growth international region include key emerge market china brazil mainly continued uptake nhl indication sale segment billion swiss franc increase constant currency growth segment come increase use patient inadequate response treatment tumour necrosis factor inhibitor shorten repeat treatment interval avastin change sale sale mchf mchf cer united states western europe japan international total sale roche group financial review roche finance report avastin advance colorectal breast lung kidney ovarian cancer relapse glioblastoma type brain tumour significant decline overall sale mainly regulatory reimbursement uncertainty begin use avastin metastatic breast cancer lead low sale affect uptake breast cancer certain european latin american market market share indication remain stable low sale europe primarily government austerity measure price cut low use breast cancer market penetration colorectal cancer remain stable despite increase competition use medicine lung cancer grow slightly number country approval december avastin frontline treatment newly diagnose advanced ovarian cancer expect positive impact sale europe onwards growth international region reflect strong uptake avastin colorectal lung cancer indication lead latin america asiapacific particularly china follow launch colorectal cancer october growth japan drive continue good uptake nonsmall cell lung cancer new metastatic breast cancer indication approve japan september expect contribute future sale november food drug administration issue final decision revoke approval avastin treatment metastatic breast cancer follow recommendation july fda expert panel agency initial notice revocation december appeal roche genentech removal indication fda decision affect medicine approve indication avastin currently approve market worldwide include recently japan breast cancer herceptin change sale sale mchf mchf cer united states western europe japan international total sale herceptin herpositive breast cancer herpositive metastatic advanced stomach cancer global sale growth drive expand access develop country increase improved testing continue uptake herpositive stomach cancer international region grow demand especially strong latin america asiapacific region high sale primarily reflect good adoption medicine stomach cancer increase western europe mainly uptake stomach cancer high penetration elderly population breast cancer enhance penetration quality test modest growth japan reflect reduction promotional activity follow earthquake march main growth contribution come sale herpositive breast cancer segment herceptin maintain high market share initial uptake new stomach cancer indication approve japanese authority march lucentis change sale sale mchf mchf cer united states total sale roche finance report roche group financial reviewlucentis wet agerelate macular degeneration amd macular edema follow retinal vein occlusion rvo sale grow dollar term billion swiss franc main factor growth amd market new rvo indication april oneyear result comparison agerelate macular degeneration treatment trial catt publish compare lucentis offlabel avastin patient wet amd limited impact sale growth total lucentis patient share wet amd segment remain stable fourth quarter report safety concern unapproved intravitreal use avastin wet amd lucentis market outside united states novartis pegasy change sale sale mchf mchf cer united states western europe japan international total sale pegasys hepatitis overall sale decline partly offset renew sale growth second half increase compare period recovery follow launch mid new directacting hepatitis medicine merck victrelis vertexs incivek new medicine design give pegylate interferon ribavirin regimen know triple combination therapy lead pegylate interferon medication pegasy position foundation triple combination therapy europe patient doctor delay start hepatitis treatment anticipation availability reimbursement triple combination therapy expect increase treatment deferral result contraction hepatitis segment mature market recent year pegasys continue expand lead market share key country japan roche merck establish strategic nonexclusive agreement improve treatment diagnosis awareness chronic hepatitis agreement roche genentech include victrelis boceprevir promotion healthcare professional use pegasys triple combination regimen pegasys prefille penproclick autoinjector make administering pegasy simple approve roll xeloda change sale sale mchf mchf cer united states western europe japan international total sale xeloda colorectal stomach breast cancer sale increase constant currency billion swiss franc growth drive primarily strong demand china brazil increase sale partly shortage certain alternative cancer medicine sale western europe impact governmentmandate price cut key market decline japan primarily effect east japan earthquake roche group financial review roche finance report tarceva change sale sale mchf mchf cer united states western europe japan international total sale tarceva advanced nonsmall cell lung pancreatic cancer overall sale increase primarily strong growth international region especially china brazil south korea drive uptake secondline treatment nonsmall cell lung cancer nsclc growth reflect continue growth nsclc firstline maintenance indication growth secondline nsclc segment highly competitive japanese market increase sale primarily uptake tarceva secondline nsclc oncologist increase confidence benefit treatment medication pricing pressure competitive challenge negatively affect sale western europe offset positive impact volume gain initial launch new firstline epidermal growth factor receptor egfr mutationpositive metastatic nsclc indication cellcept change sale sale mchf mchf cer united states western europe japan international total sale cellcept prevention solid organ transplant rejection sale decline sharply continued generic erosion western europe follow patent expiry respectively sale country international region negatively affect price pressure increase use generic continue growth japan reflect position cellcept standard care approve indication neorecormonepogin change sale sale mchf mchf cer united states western europe japan international total sale neorecormonepogin anemiarenal anemia highly competitive market group overall market share anemia franchise slightly year combine sale roche neorecormon chugais epogin epoetin beta decline constant currency western europe international region sale lower increase biosimilar competition market decline cancerrelate anemia segment competitive pressure low reimbursement price result reduce sale epogin japan roche finance report roche group financial reviewthe sustained decline sale neorecormon epogin partly offset strong growth sale longeracte erythropoiesisstimulate agent mircera methoxy polyethylene glycolepoetin beta rise constant exchange rate million swiss franc growth increase number patient switch start treatment mircera place neorecormonepogin strong contribution high mircera sale come japan product launch chugai july international region account total mircera sale bonvivaboniva change sale sale mchf mchf cer united states western europe japan international total sale bonvivaboniva osteoporosis sale western europe low entry generic market pricing reimbursement issue decrease reflect fall market demand reserve adjustment strong growth asiapacific constant currency lead south korea offset low sale rest international region notably eastern european country brazil actemraroactemra change sale sale mchf mchf cer united states western europe japan international total sale actemraroactemra rheumatoid arthritis systemic juvenile idiopathic arthritis sale continue grow strongly approve indication region sale increase particularly actemra continue gain market share western europe japan latin america marketing reimbursement approval additional country continue expand patient access actemraroactemra sustain growth uptake later line therapy depend approve indication sale japan grow strongly increase use actemra firstline later line therapy support recognition high remission rate achieve medicine tamiflu change sale sale mchf mchf cer united states western europe japan international total sale roche group financial review roche finance report tamiflu influenza follow unprecedented demand influenza pandemic sale continue decline strongly reflect baseline effect moderate influenza season hemisphere significantly high sale government particularly japan international region notably brazil south korea taiwan mexico limit sale government primarily drive replacement expire pandemic stockpile zelboraf change sale sale mchf mchf cer united states western europe japan international total sale zelboraf braf vmutate metastatic melanoma food drug administration approve zelboraf august enable genentech launch new target cancer medicine united states month marketing application file fda simultaneously approve roche diagnostic cobas braf mutation test companion diagnostic identify patient treatment zelboraf appropriate initial sale zelboraf strong broad payer coverage achieve marketing approval obtain switzerland brazil fourth quarter december european medicine agencys committee medicinal product human use chmp unanimously recommend zelboraf grant marketing approval marketing application file number country include australia new zealand rate malignant melanoma high pharmaceutical division sale region change sale sale region mchf mchf cer united states western europe japan international cemai latin america asiapacific region total sale central eastern europe middle east africa central asia indian subcontinent united states sale grow dollar term growth drive lucentis mabtherarituxan actemra herceptin offset decline avastin sale addition impact healthcare reform lead reduction sale approximately million dollar million swiss franc increase rebate affect major product compare million dollar million swiss franc western europe sale decrease constant currency despite growth oncology product mabthera rituxan herceptin uptake actemraroactemra decline low avastin sale continue impact generic erosion cellcept bonvivaboniva sale low sale neorecormon highly competitive renal anemia market addition estimate million euro million swiss franc negative impact european austerity measure compare million euro million swiss franc roche finance report roche group financial reviewjapan decrease sale japanese yen term primarily direct indirect effect earthquake march decline government purchase tamiflu emergency relief effort rapid implementation chugai recovery programme ensure product supply restore production take priority marketing activity normal operation resume end ensure uninterrupted supply medicine patient shipment control introduce number key product immediately follow earthquake case control maintain fourth quarter promotional activity reduce accordingly addition half residual effect mandatory twoyearly pharmaceutical price cut implement april growth avastin launch mircera high actemra sale offset low sale epogin pegasys kytril international asiapacific show particularly strong growth lead oncology franchise selling product herceptin mabtherarituxan avastin china main driver overall sale growth growth latin america mainly oncology product especially herceptin mabtherarituxan avastin mexico negative impact biosimilar competition actemraroactemra sale continue grow latin america increase underlying sale growth brazil south korea offset significantly low tamiflu sale exclude tamiflu growth respectively exclude tamiflu total sale key emerge market grow sale exclude tamiflu cemai subregion decline political development north africa middle east price pressure eastern european market pharmaceutical division sale lead emerge market change change cer cer exclude sale sale country mchf mchf total tamiflu brazil china india mexico russia south korea turkey total sale operating result pharmaceutical division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty income increase constant exchange rate mainly result high lucentis royalty increase constant currency outlicense agreement drive milestone income marcadia compound lucentis high income profit sharing agreement income disposal product relatively stable roche group financial review roche finance report pharmaceutical division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement restructuring expense impairment property plant equipment cost sale core basis global restructure operational excellence amortisation intangible asset impairment intangible asset east japan earthquake total ifrs basis cost sale core basis decrease constant currency mainly result low royalty expense percentage sale cost sale increase slightly increase manufacturing cost good sell period cost mainly product mix effect startup activity product launch inventory writeoff second half royalty expense low mainly arise expire royalty obligation herceptin major country begin late low sale tamiflu contractual change sale bonvivaboniva partly offset royalty expense million swiss franc relate rituxan arbitration note consolidated financial statement expense collaboration profitshare agreement decrease estimated million swiss franc recoverable respect rituxan arbitration mention site closure disposal cost manufacture logistic area million swiss franc record operational excellence programme addition east japan earthquake million swiss franc cost report impairment repair maintenance plant writeoff raw material intermediate chugai pharmaceutical division marketing distribution change mchf mchf cer marketing distribution core basis global restructure operational excellence east japan earthquake total ifrs basis core cost decrease tight cost management saving operational excellence programme percentage sale cost decrease percentage point sale marketing effort focus oncology portfolio rollout additional approve indication avastin mabtherarituxan herceptin continue rollout actemraroactemra rheumatoid arthritis cost incur continued support pegasys xeloda tarceva significant bad debt provision expense total million swiss franc incur particular southern european country noncore cost million swiss franc record operational excellence programme relate employee termination cost roche finance report roche group financial reviewpharmaceutical division research development change mchf mchf cer research development core basis global restructure operational excellence amortisation intangible asset impairment intangible asset total ifrs basis core cost low resource prioritisation saving operational excellence programme research development cost percentage sale compare oncology remain main focus area high investment central nervous system virology offset low lifecycle investment metabolism inflammation operational excellence cost million swiss franc relate primarily site disposal property plant equipment impairment impairment charge intangible asset relate asset acquire alliance transaction acquisition majority large impairment arise project termination operational excellence programme addition pharmaceutical division spend million swiss franc inlicense acquire pipeline compound technology capitalise intangible asset pharmaceutical division general administration change mchf mchf cer administration restructuring expense gain loss disposal property plant equipment business taxis general item general administration core basis global restructure operational excellence global restructure genentech transaction alliance business combination legal environmental settlement east japan earthquake total ifrs basis core cost increase mainly new brand pharmaceutical product fee cost impact million swiss franc exclude fee constant currency core cost decrease drive low administration cost saving organisational shift certain finance function corporate noncore cost general administration area include cost million swiss franc relate operational excellence consist mainly site disposal cost site boulder colorado madison wisconsin site kulmbach germany cost partly offset gain disposal site palo alto california additionally itrelate expense operational excellence alliance business combination include million swiss franc relate reversal provision contingent consideration arrangement business combination roche group financial review roche finance report financial position pharmaceutical division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventory payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give currency translation effect balance sheet amount half swiss franc strengthen currency follow intervention swiss central bank trend reverse second half result end dollar exchange rate start year euro slightly weak swiss franc japanese yen strengthen swiss franc yearonyear swiss franc strengthen currency brazilian real turkish lira overall effect completely net total net operating asset pharmaceutical division consolidated swiss franc net work capital decrease constant currency mainly decrease inventory receivables prepaid expense balance sheet value inventory decrease mainly inventory writeoff second half certain buildup key growth market china asiapacific latin america region trade receivables increase main factor increase public sector receivables southern european country particularly spain portugal continue growth business china increase offset decrease million swiss franc follow settlement public sector trade receivables government bond greece payables increase slightly accrue royalty liability increase longterm net operating asset property plant equipment decrease mainly site divestment operational excellence programme time addition completion new manufacturing facility expansion technical research development facilities basel switzerland penzberg germany goodwill intangible increase mainly acquisition anadys pharmaceutical decrease provision mainly relate settlement obligation operational excellence programme roche finance report roche group financial reviewfree cash flow pharmaceutical division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital receivables inventory payable total increase decrease net working capital investment property plant equipment investment intangible asset total investment operate free cash flow sale detail breakdown provide pharmaceutical division generate strong operating free cash flow billion swiss franc increase constant currency compare drive strong operating profit performance low capital expenditure offset increase work capital trade receivables increase partly result continue sale growth china factor significant increase trade receivables public sector customer southern european country particularly spain portugal measure take improve collection country include intense communication customer negotiation payment plan charge interest late payment legal action cash flow perspective cash invest inventory increase growth key growth market asiapacific latin america especially china payable increase increase accrue royalty liability operate profit cash adjustment decrease mainly significant cash outflow utilisation operational excellence programme provision low depreciation amortisation impairment partially offset cash receive disposal roche group financial review roche finance report diagnostic division operating result diagnostic division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale diagnostic business continue increase sale significantly vitro diagnostic ivd global market growth constant currency professional diagnostic sale growth leverage immunodiagnostic tissue diagnostic sale growth drive sale advance stain market main growth contributor business area grow twice rate respective market diabetes care sale increase million swiss franc increase constant currency sale molecular diagnostic total million swiss franc increase drive virology segment apply science sale decrease yearonyear decline influenza virus testing increase competition sequence slowdown research fund roche finance report roche group financial reviewdiagnostic division sale business area change sale sale business area mchf mchf cer professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic total sale professional diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale professional diagnostic sale grow double rate global market especially strong growth emerge market early roche professional diagnostic take leading position market include ivd product clinical laboratory hospitalambulatory pointofcare testing key driver growth growth immunoassay business roche broad menu offer industry test growth clinical chemistry business instrument placement despite temporary disruption supply instrument manufacturing partner hitachi high technology east japan earthquake growth coagulation monitor business ongoing conversion patient selfteste lead increase professional diagnostic lead market share sector despite introduction new anticoagulant therapie market emea europe middle east africa north america region business maintain growth market level particularly increase market penetration north america international region continue abovemarket growth lead asiapacific latin america investments china contribute growth strengthen roche professional diagnostic market leadership position country year business launch seven new immunoassay cobas clinical chemistry module new immunoassay hbsag quant assay determine hepatitis viral load pegasys therapy immunoassay help detect early ovarian cancer vitamin total measurement vitamin business complete acquisition pvt leader laboratory automation workflow early acquire verum diagnostica lead company platelet function test roche group financial review roche finance report diabetes care change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale diabetes care sale increase slightly environment impact price pressure slow volume growth increase regulatory requirement particularly growth rest world region partly offset reduce sale north america despite challenge market diabetes care remain leader global blood glucose monitoring hold close global market main growth driver new generation accuchek monitoring system accuchek combo combine insulin pump meter good sale development product emea rest world region help strengthen roche diabetes care market position especially strong growth asiapacific latin america decline sale mainly postpone launch late addition new accuchek portfolio fdas clearance new maltoseindependent chemistry accuchek aviva plus test strip quarter mark step bring new portfolio expect drive future growth key market late roche diabetes care start launch generation stripfree meter accuchek mobile australia netherland insulin delivery segment insulin pump sale grew drive mainly increase number patient accuchek combo sale infusion set negatively impact voluntary recall accu chek flexlink plus molecular diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale molecular diagnostic growth sale strong performance north america rest world region notably united states china roche molecular diagnostic retain leadership position global molecular diagnostic market close global market large expand test menu business main sale growth come hiv hbv viral load test blood screening business grow emea region spite pricing pressure virology blood screen segment overall business remain stable majority share market fda approval human papillomavirus hpv test april business enter large single fast grow molecular testing market hpv test experience positive uptake previously launch tender karolinska university hospital sweden large pilot project hpv primary screen partnership contract sign major laboratory physician sale force start expand hpv business business area continue build novel oncology portfolio launch test detect cancerrelate mutation braf melanoma egfr lung cancer kra colorectal cancer gene complement roche portfolio companion diagnostic cobas braf test see strong market uptake available europe america asiapacific development personalise healthcare come partnership large pharmaceutical company include merck clovis continue internal roche project future assays detection biomarker roche finance report roche group financial reviewapplied science change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale apply science sale decline drive emea north america region japan slowdown research funding increase competition gene sequence yearonyear effect large order influenza testing early effect especially mark asiapacific region sale decline exclude effect sale asiapacific increase custom biotech biochemical business account approximately apply science revenue continue healthy growth increase sale business supply product healthcare industry include specialty biochemical new bioprocess analyser instrument placement decline genomics pcr analysis business lead reduction sale respectively despite product continue gain market share generate growth include test kit junior benchtop system gene sequence test kit magna pure dna sample preparation seqcap microarray target sequence major launch year lightcycler nano small affordable instrument automise pcr analysis tissue diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale tissue diagnostic sale grow substantially ahead market region reinforce business leadership position tissuebase cancer diagnostic emea japan sale grow double market rate reflect intensify uptake roche tissue diagnostic automate solution novel advanced stain test region growth drive increase instrument placement increase sale immunohistochemistry ihc situ hybridisation ish assay detect protein gene tissue sample include new antibody ihc testing business industryleade test menu include readytouse antibody test newly launch optiview system improve sensitivity visualisation ihc assays enable pathologist improve detection biomarker tissue sample june roche tissue diagnostic launch dual ish test support personalise breast cancer treatment test see rapid uptake worldwide achieve leadership position market combine ihc test companion algorithm analytical imaging software business offer complete diagnostic workflow laboratory business complete acquisition mtm laboratory leader cervical cancer vitro diagnostic roche group financial review roche finance report diagnostic division sale region change sale sale region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sale sale continue grow region asiapacific region achieve strong growth lead china grow south korea grow growth drive mainly professional diagnostic partly offset lower apply science sale nonrecurrence order half relate influenza test despite pricing challenge emea europe middle east africa north america sale region grow respectively drive professional diagnostic north america division market share continue grow vitro diagnostic business strong sale area offset decline diabetes care sale follow postpone launch japan good performance professional diagnostic tissue diagnostic partly offset low sale apply science result total sale growth diagnostic division sale lead emerge market change sale sale country mchf mchf cer brazil china india mexico russia south korea turkey total sale sale growth emerge market lead china contribution russia south korea strong growth china drive demographic change healthcare reform foresee investment billion dollar primary healthcare year provide national insurance plan population growth china particularly strong professional diagnostic molecular diagnostic business significant growth russia achieve win major tender mainly professional diagnostic molecular diagnostic relate russian healthcare modernisation programme operating result diagnostic division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis decrease royalty operating income fall royalty income result patent expiration taqman pcr patent molecular diagnostic high royalty expense royalty income payment patent owner molecular diagnostic idaho pcr contract professional diagnostic hcv bioprocess patent roche finance report roche group financial reviewdiagnostic division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructure operational excellence amortisation product intangible impairment product intangible total ifrs basis growth core cost low sale growth result low costofsale ratio previous cost reduction initiative centralisation logistic service harmonisation technical service practice renegotiation supplier contract continue positive impact partly compensate high depreciation installation cost technical service cost continue investment expand market share meter placement increase instal instrument base decrease royalty expense million swiss franc patent expiration certain inlicense intellectual property operational excellence programme cost million swiss franc incur mainly relate employeerelate cost graz austria rotkreuz burgdorf switzerland decrease amortisation constant currency mainly certain asset fully amortise partly offset amortisation recently acquire intangible asset medingo mtm laboratory second half impairment million swiss franc book intangible sequence array business diagnostic division marketing distribution change mchf mchf cer marketing distribution core basis global restructure operational excellence amortisation intangible asset total ifrs basis marketing distribution cost increase reflect high cost molecular diagnostic notably microbiology area launch cobas hpv dna test professional diagnostic immunoassay clinical chemistry segment remain high contributor particular increase distribution cost follow east japan earthquake lead change shipping air freight increase come high marketing support advance stain assay portfolio tissue diagnostic work flow automation coagulation monitor sector professional diagnostic core basis marketing distribution cost percentage sale compare roche group financial review roche finance report diagnostic division research development change mchf mchf cer research development core basis global restructure operational excellence amortisation intangible asset impairment intangible asset total ifrs basis research development core cost increase drive development newgen instrument new personalise healthcare oncology test molecular diagnostic micropump diabete care digital pathology product tissue diagnostic investment new immunoassay laboratory coagulation portfolio professional diagnostic percentage sale core research development cost increase operational excellence expense million swiss franc mainly employeerelate cost graz austria diagnostic division general administration change mchf mchf cer administration restructuring expense gain loss disposal property plant equipment general item general administration core basis global restructure operational excellence alliance business combination legal environmental settlement total ifrs basis general administration cost decrease mainly cost transfer logistic centre brazil operational excellence cost million swiss franc consist mainly reorganisation expense financial position diagnostic division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventory payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give roche finance report roche group financial reviewcurrency translation effect balance sheet amount half swiss franc strengthen currency follow intervention swiss central bank trend reverse second half result end dollar exchange rate start year euro slightly weak swiss franc japanese yen strengthen swiss franc yearonyear swiss franc strengthen currency brazilian real turkish lira overall effect largely net total net operating asset diagnostic division consolidated swiss franc net work capital increase constant currency drive increase receivables inventory main factor increase buildup trade receivable certain southern european country increase inventory level product launch like cobas inventory increase related acquisition buildup hitachisource analyser earthquake japan receivables decrease million swiss franc follow settlement public sector trade receivables government bond greece payable high accelerate effort increase harmonise supplier payment term longterm net operating asset total balance constant currency increase investment property plant equipment notably instrument placement customer partially offset decrease intangible asset increase provision mainly operational excellence employeerelate cost free cash flow diagnostic division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment increase decrease net work capital receivables inventory payable total increase decrease net working capital investment property plant equipment investment intangible asset total investment operate free cash flow sale detail breakdown provide operate free cash flow diagnostic division decrease constant currency translation swiss franc compare increase operating profit offset increase net work capital arise increase trade receivable overall high inventory level partly offset high payable increase trade receivable long settlement time particularly southern europe reduce factoring activity high inventory level result launch growth key product professional diagnostic tissue diagnostic high stock product source japan payable high accelerated effort increase harmonise supplier payment term overall negative effect operate free cash flow margin percentage point roche group financial review roche finance report corporate operating result corporate operating result summary change mchf mchf cer administration gain loss divestment subsidiary restructure expense general item general administration cost core basis global restructure legal environmental settlement total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result core eps general administration cost increase constant currency high administration expense constant currency result shift certain finance function pharmaceutical division corporate total cost ifrs basis grow constant currency million swiss franc million swiss franc high rate core cost operational excellence restructuring expense million swiss franc higher compare year expense corporate operating free cash flow show increase net outflow drive high allocate administration expense continuous change organisational structure roche finance report roche group financial reviewforeign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer swiss francs change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy average rate euro dollar major currency low swiss franc compare sale development result negative impact percentage point translate growth constant currency decline swiss franc term core operating profit negative impact high percentage point different currency structure operating cost sale core operate profit growth constant currency translates decline currency translation exposure operating profit mitigate group majority cost base locate outside switzerland sensitivity group sale core operating profit absolute term movement foreign currency swiss franc show table currency sensitivity impact rise average exchange rate sale core operating profit versus swiss franc mchf mchf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany obviously large majority chugais cost denominate japanese yen roche group financial review roche finance report treasury taxation result treasury taxation result change change mchf mchf chf cer ifrs result operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position treasury taxation net debt pension income taxis financial longterm asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury taxation treasury activity taxis pay dividend pay total page definition core result core ep roche finance report roche group financial reviewfinancial income financial income million swiss franc increase constant exchange rate swiss franc interest income income debt security million swiss franc remain low level low prevailing interest rate net foreign exchange result gain million swiss franc compare loss million swiss franc improvement foreign exchange gain million swiss franc venezuela follow enactment law allow group benefit predevaluation treatment certain transaction contrast group incur loss million swiss franc cause currency devaluation venezuela net income equity security million swiss franc million swiss franc expect return pension plan asset million swiss franc cer overall low assumption expect return analysis financial income give note consolidated financial statement financing cost finance cost million swiss franc decrease million swiss franc constant exchange rate swiss franc main driver decrease interest expense million swiss franc decrease constant currency reflect continue repayment debt incur finance genentech transaction translation effect strong swiss franc financing cost include million swiss franc early redemption debt compare million swiss franc describe note consolidated financial statement interest cost pension plan million swiss franc decrease cer low discount rate analysis financing cost give note consolidated financial statement income taxis group effective core tax rate decrease percentage point decrease mainly relatively low percentage profit contribution high tax jurisdiction notably japan decrease statutory tax rate basel switzerland addition driver mention ifrs effective tax rate decrease increase tax benefit equity compensation plan compare detail group income tax position give note consolidated financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate core basis global restructure intangible asset group effective tax rate ifrs basis roche group financial review roche finance report financial position decrease net debt mainly positive free cash flow generation fully describe net debt section increase net pension liability reflect fall interest rate lead discount define benefit obligation high detail give pension section net tax liability decrease mainly deferred tax benefit increase net pension liability recognise equity fact taxis pay exceed total income tax expense net derivative position decrease billion swiss franc mainly low valuation crosscurrency swap follow strong dollar compare euro interest payable relate bond note coupon payment date march decline debt repayment december group hold financial longterm asset market value billion swiss franc compare consist holding biotechnology company acquire context licensing transaction scientific collaboration free cash flow cash outflow treasury activity increase slightly billion swiss franc high foreign exchange loss low gain marketable security partially offset low interest payment total taxis pay billion swiss franc increase constant exchange rate prepayment tax settlement certain outstanding tax position partly offset low tax payment chugai total dividend pay billion swiss franc increase billion swiss franc compare reflect increase roche group dividend net debt net debt million chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt period december cash cash equivalent marketable security longterm debt shortterm debt net debt end period roche finance report roche group financial reviewnet debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollar denominate debt include bond note denominate euros swiss franc pound sterling swap dollar financial statement economic characteristic equivalent dollardenominate bond note net debt position group end billion swiss franc decrease billion swiss franc billion swiss franc start year mainly free cash flow billion swiss franc describe outflow billion swiss franc come transaction equity instrument execute cover exposure equity compensation plan issue employee addition billion swiss franc pay business combination year group receive billion swiss franc hedge collateral agreement set follow finance genentech transaction previously describe annual financial statement issue debt finance genentech transaction group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar total exposure hedge issuance bond note approximately billion swiss franc note collateral agreement enter derivative counterpartie mitigate counterparty risk cash collateral billion swiss franc deliver roche increase cash collateral balance favour roche billion swiss franc start year billion swiss franc december collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro swiss franc pound sterling currently collateral balance move approximately million dollar foreign exchange rate simultaneously collateral volatility decrease million dollar movement foreign exchange rate mid nonus dollardenominated bond note repay realise gain derivative billion swiss franc relate mainly hedge nonus dollardenominate bond note debt repayment billion swiss franc largely absorb free cash flow billion swiss franc significant impact net debt position detail group marketable security cash debt position give note consolidated financial statement roche group financial review roche finance report pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation minor relatively remote possibility arise fund asset management group define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource fund status balance sheet position mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability funding status overall funding status group define benefit plan decrease compare start year decrease came mainly increase define benefit obligation arise fall discount rate comparison end plan asset broadly stable company contribution increase million swiss franc compare million swiss franc group continues closely monitor fund status major pension fund addition cash injection group initiate plan change local pension plan example major pension fund remove early retirement incentive group continue introduce flexible retirement model well accommodate diverse need age workforce expense record income statement total pension expense relate group define benefit plan million swiss franc compare million swiss franc increase primarily low curtailment gain million swiss franc compare million swiss franc addition million swiss franc past service cost million swiss franc past service income result oneoff plan amendment group base revise actuarial assumption end total pension expense expect broadly stable compare detail group pension postemployment benefit give note consolidated financial statement roche finance report roche group financial reviewroche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group healthcare company list term total shareholder return tsr share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group actual constant exchange rate share price healthcare outperform sector despite continue pressure healthcare price sovereign debt issue europe usa good roche news flow reward relatively strong share price performance peer group abbott laboratories amgen astella astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index roche group financial review roche finance report propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page finance report information share nonvoting equity security change chf chf chf basic eps dilute eps core eps equity attributable roche shareholder share dividend share detail refer note consolidated financial statement page finance report payout ratio calculate dividend share divide core earning share roche bond note finance genentech transaction group issue bond note equivalent billion swiss franc february march year debt raise early repay december include early redemption billion dollar note originally march march repurchase million euro note originally march june follow tender offer repurchase million swiss franc note originally march november follow tender offer repurchase million pound sterling note originally march december follow tender offer repurchase million pound sterling note originally august december follow tender offer maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction roche finance report roche group financial reviewbond note nominal amount december contractual maturity dollar euro pound sterling swiss franc principal principal principal principal total total musd meur mgbp mchf musd mchf total total translate december exchange rate proceed bond note swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate ongoing business free cash flow billion swiss franc include cash generate operation payment interest tax dividend second half free cash flow inflow billion swiss franc half free cash flow outflow billion swiss franc include billion swiss franc payment annual dividend describe commentary net debt position group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk shortterm financing requirement group commercial paper programme united states issue billion dollar unsecured commercial paper note commit credit line billion euro available backstop line commercial paper note total billion dollar outstanding december longerterm financing group maintain strong longterm investmentgrade credit rating standard poor moodys upgrade september facilitate efficient access international capital market credit rating roche group december shortterm longterm outlook moodys stable standard poor stable roche group financial review roche finance report financial risk december group net debt position billion swiss franc december billion swiss franc financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security mchf total mchf total cash cash equivalent money market instrument bond debenture investment share total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group billion swiss franc fix income marketable security remain strong invest aaaa range note previously group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables billion swiss franc begin increase financial difficulty certain southern european country include spain italy portugal greece group lead supplier country trade receivable billion swiss franc public customer country group use different measure improve collection country include intense communication customer negotiation payment plan charge interest late payment legal action group apply delivery cash public hospital greece second half group accept offer greek government settle billion euro trade receivables zero coupon government bond redeemable group sell vast majority bond remain bond carry value million swiss franc account receivables scope bond settlement provide december reflect bond settlement term available settlement term imply discount million euro average discount include result total financial result trade receivables zero coupon bond scope settlement expense million swiss franc include interest income gain loss sale bond impairment remain position market value december liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year despite total debt billion swiss franc december roche enjoy strong longterm investmentgrade credit rating standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total billion swiss franc december billion swiss franc billion swiss franc serve backstop line commercial paper programme december debt draw credit line roche finance report roche group financial reviewmarket risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price var datum table indicate economic loss level period month probability exceed actual future economic gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include credit risk component market risk financial instrument december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total interest rate var decrease reflect age debt repayment debt issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var increase slightly low diversification effect price risk arise mainly movement price equity security remain largely stable december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration information financial risk management financial risk var methodology include note consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement amendment exist standard interpretation material impact group overall result financial position new standard issue describe note consolidated financial statement implement latest note base initial analysis date group anticipate material impact group overall result financial position matter revise version ias employee benefit include follow change exist standard eliminate option defer recognition actuarial gain loss define benefit postemployment plan know corridor method group currently apply option use option recognise gain loss directly equity option currently apply group henceforth requirement revise standard change impact group financial statement current method include expect income plan asset estimate asset return replace discount rate discount define benefit obligation base initial review group estimate method apply consolidated financial statement net financial income approximately million swiss franc lower publish operating profit materially affect roche group financial review roche finance report roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group roche group consolidate financial statement roche finance report roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset associate financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche group roche group consolidate financial statement roche finance report roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease work capital payment define benefit postemployment plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity instrument finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group roche group consolidated financial statementsroche group consolidate statement change equity million chf reserve non share retain fair control total capital earning value hedge translation total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest movement december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest december roche group roche group consolidate financial statement roche finance report note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder march preparation consolidate financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change change accounting policy arise application new revise standard interpretation apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result comparative period opening balance period restate new accounting policy apply case transitional requirement particular standard interpretation specify change apply prospectively prospective application require new accounting policy apply result current period comparative period restate addition comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right currently exercisable potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control roche finance report roche group note roche group consolidated financial statementsinvestment associate account equity method company group exercise power exercise significant influence control normally evidence group own voting right currently exercisable potential voting right company balance transaction associate result unrealised income eliminate extent group interest associate interest joint venture report linebyline proportionate consolidation method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include cec global group function communication human resource finance include treasury taxis pension fund management include corporate legal corporate safety environmental service subdivisional information roche pharmaceutical chugai operate segment pharmaceutical division present transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income disposal foreign entity identify cumulative currency translation difference comprehensive income relate foreign entity recognise income gain loss divestment roche group note roche group consolidate financial statement roche finance report revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research cost cost incur purpose gain new scientific technical knowledge understanding cost expense incur internal development cost cost incur application research finding knowledge plan develop new product commercial production cost qualify capitalisation intangible asset follow criterion demonstrate technical feasibility complete development project successfully available use sale intention complete development project ability use sell result development project development project generate economic benefit normally evidence existence size market result project product result project availability adequate technical financial resource complete development project ability measure development expenditure reliably qualify capitalisation intangible asset development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation meet prior obtain marketing approval regulatory authority major market internal development cost meet criterion expense incur postmarkete study regulatory approval phase cost pharmaceutical business expense incur generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason safety surveillance design detect rare longterm adverse effect large patient population long time period possible early stage development cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure roche finance report roche group note roche group consolidated financial statementsin addition internal research development activity group party inlicense similar arrangement alliance partner group acquire inprocess research development asset business combination purchase specific asset inprocess research development resource acquire inlicense arrangement business combination separate purchase capitalise intangible asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy review impairment set impairment property plant equipment intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost available use intangible asset amortise straightline basis period expect benefit review impairment reporting date research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth long term expect rate return plan asset discount rate base market yield highquality corporate bond country concern past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly comprehensive income pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly comprehensive income roche group note roche group consolidate financial statement roche finance report equity compensation plan certain employee group participate equity compensation plan include separate plan genentech prior genentech transaction chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity cash settle plan liability record measure fair value report date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor primarily occur diagnostic division asset subject finance lease initially report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease subsequently recognise earn income term lease base effective interest rate method lease income operating lease recognise lease term straightline basis roche finance report roche group note roche group consolidate financial statementsbusiness combination goodwill business combination account acquisition method accounting consideration transfer business combination measure fair value date acquisition consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group fair value consideration transfer include contingent consideration arrangement fair value directly attributable acquisitionrelated cost expense current period report general administration expense date acquisition group recognise identifiable asset acquire liability assume noncontrolle interest acquire business identifiable asset acquire liability assume initially recognise fair value group acquire ownership acquire business noncontrolle interest record proportion fair value acquire net asset attributable noncontrolle interest goodwill record surplus consideration transfer group interest fair value acquire net asset goodwill fair value adjustment record asset liability acquire business functional currency business initial accounting business combination incomplete end reporting period provisional amount measurement period provisional amount retrospectively adjust additional asset liability recognise reflect new information obtain fact circumstance exist acquisition date affect measurement amount recognise date know measurement period exceed month date acquisition goodwill amortise assess possible impairment reporting date additionally test annually impairment goodwill arise investment associate surplus cost investment group share fair value net identifiable asset goodwill record investment associate change ownership interest subsidiary account equity transaction occur control obtain result loss control intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy roche group note roche group consolidate financial statement roche finance report impairment goodwill goodwill assess possible impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss methodology impairment testing describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record difference carry value estimate recoverable objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise consolidated income statement marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition statement cash flow provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available fair value hierarchy valuation technique incorporate observable market datum market condition factor likely affect fair value financial instrument valuation technique typically derivative financial instrument fair value financial asset liability report date materially different report carry value specifically mention note consolidated financial statement information fair value hierarchy include note risk management roche finance report roche group note roche group consolidate financial statementsfinancial asset financial asset principally investment include marketable security classify fairvaluethroughprofit orloss availableforsale heldtomaturity loan receivables fairvaluethroughprofitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethrough profitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset security fix maturity group intent ability hold maturity loan receivables financial asset create group acquire issuer primary market nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale financial asset initially record fair value include transaction cost asset fairvaluethrough profitorloss exclude transaction cost purchase sale recognise settlement date fairvalue throughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record comprehensive income interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose cumulative gain loss previously recognise comprehensive income include financial income current period loan receivables subsequently carry amortise cost effective interest rate method financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity security market value original cost net previous impairment consider impair availableforsale equity security market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record comprehensive income objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost net previous impairment fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer interest transfer financial asset create retain group recognise separate asset liability derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedging instrument discuss hedge accounting policy change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract carry amortise cost roche group note roche group consolidate financial statement roche finance report hedge accounting purpose hedge accounting hedging relationship type fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence cash flow hedge hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include comprehensive income remain ineffective portion report financial income hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial asset liability cumulative change fair value hedge instrument record comprehensive income include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include comprehensive income remain ineffective portion record financial income hedge instrument derivative comprehensive income case entity dispose cumulative change fair value hedge instrument record comprehensive income reclassify income debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method group derecognise financial liability contractual obligation discharge cancel expired taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future roche finance report roche group note roche group consolidate financial statementsdeferred income tax asset liability recognise temporary difference tax basis asset liability carry value financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate discontinue business noncurrent assetsheldforsale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion classify heldforsale early disposal group group assets dispose group single transaction liability directly associate asset transfer transaction asset liability disposal group reclassify heldforsale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification heldforsale measurement asset liability disposal group update accordance applicable accounting policy initial classification hold sale disposal group recognise low carrying value fair value cost sell impairment loss initial classification heldforsale include income statement equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet potential obligation employee arise respect certain group equity compensation plan management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated financial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement consolidation subsidiary associate group periodically undertake transaction involve obtain right control significantly influence operation company transaction include acquisition equity company purchase certain asset assumption certain liability contingent liability company enter alliance agreement company include transaction involve special purpose entity similar vehicle case management make assessment group right control significantly influence company operation base assessment company consolidated subsidiary associate company make assessment management consider underlie economic substance transaction contractual term roche group note roche group consolidate financial statement roche finance report business combination group acquire control business consideration transfer allocate identifiable asset acquire liability assume noncontrolle interest acquire business residual record goodwill process involve management make assessment fair value item management judgement particularly involve recognition measurement follow item intellectual property include patent licence trademark similar right currently market product right scientific knowledge associate project currently research development phase contingency legal environmental matter contingent consideration arrangement recoverability accumulate tax loss previously incur acquire company case management make assessment base underlying economic substance item concern contractual term order fairly present item lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider operate lease finance lease make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base result new information experience change recognise period estimate revise key assumption future key source estimation uncertainty significant risk cause material adjustment carry value asset liability month describe revenue recognition circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary sale allowance group provision accrual expect sale return chargeback rebate include medicaid united states similar rebate country december total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total provision accrual item adequate base currently available information deduction base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently level sale recognise income statement future period roche finance report roche group note roche group consolidated financial statementsallowance doubtful account receivable group provision accrual doubtful receivables december total million swiss franc note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account economic condition management believe total provision accrual item adequate base currently available information provision base management estimate subject change well information available change arise impact provision accrual recognise balance sheet future period consequently market distribution expense recognise income statement future period property plant equipment intangible asset include goodwill group property plant equipment carry value million swiss franc disclose note goodwill carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment change discount rate lead impairment pension postemployment benefit group employee participate postemployment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group company party legal proceeding include claim arise trade significant matter describe note legal provision december total million swiss franc management believe total provision legal proceeding adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site include landfill treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site method extent remediation percentage problematic material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure change arise impact provision recognise balance sheet future period roche group note roche group consolidate financial statement roche finance report income taxis december net liability current income taxis million swiss franc net asset defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy change ifrs implement group implement minor amendment exist standard interpretation material impact group overall result financial position new revise standard follow new standard issue international accounting standard board iasb implement late ifrs consolidated financial statement ifrs joint arrangement ifrs disclosure interest entity ifrs fair value measurement ia revise employee benefit addition revision issue ifrs financial instrument implementation date standard defer late group currently assess potential impact new revise standard interpretation effective january group early adopt note base analysis date group anticipate material impact group overall result financial position matter revise version ias employee benefit include follow change exist standard eliminate option defer recognition actuarial gain loss define benefit postemployment plan know corridor method group currently apply option use option recognise gain loss directly comprehensive income option currently apply group henceforth requirement revise standard change impact group financial statement current method include expect income plan asset estimate asset return replace discount rate discount define benefit obligation base initial review group estimate method apply consolidated financial statement net financial income approximately million swiss franc lower publish operating profit materially affect roche finance report roche group note roche group consolidate financial statement operating segment information divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset impairment net assetsheldforsale equity compensation plan expense roche group note roche group consolidate financial statement roche finance report pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result subdivisional profit elimination profit division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset impairment net assetsheldforsale equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group nonoperate asset liability consist primarily balance relate treasury pension taxation matter roche finance report roche group note roche group consolidated financial statementsnet operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group note roche group consolidate financial statement roche finance report supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members december major customer national wholesale distributor amerisourcebergen corp represent approximately billion swiss franc billion swiss franc group revenue approximately revenue pharmaceuticals operating segment residual diagnostic segment group report substantial revenue national wholesale distributor cardinal health inc mckesson corp total customer represent approximately quarter group revenue chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone result jgaap basis result chugai consolidated roche group accordance ifrs roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche roche finance report roche group note roche group consolidated financial statementsunder rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item east japan earthquake march severe earthquake tsunami strike pacific coast tohoku japan consequence chugais operation japan limited impact disaster carefully review operation manufacturing process supply chain damage chugais utsunomiya manufacturing plant result operation temporarily halt production product plant fully resume end august cost record damage cause earthquake mainly relate utsunomiya plant consist impairment restoration cost building partially damage facility writeoff intermediate finish product cost shutdown net amount receive insurance cost record show chugais contract manufacturer affect earthquake result product shipment control last end october chugais promotional activity japan affect event cancel employee resource divert ensure continued product supply information flow customer factor certain negative impact chugais sale second half global issue east japan earthquake cost millions chf cost sale marketing distribution general administration total matter detail chugais equity compensation plan give note roche group note roche group consolidate financial statement roche finance report financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity security derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security gain loss debt security derivative net writedown impairment longterm loan net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation debt discount gain loss debt derivative net gain loss redemption repurchase bond note net time cost provision interest cost define benefit plan total financing cost net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income roche finance report roche group note roche group consolidate financial statement income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total income expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate average expect rate decrease compare main driver decrease come japan relatively high local tax rate average group rate group taxable profit japan decrease result decrease percentage japan contribute overall mix group profit low profit japan mainly direct indirect effect east japan earthquake chugais result discuss note significant local tax rate change main operating area group compare decrease statutory tax rate basel switzerland group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development manufacturing tax credit state tax impact difference group effective tax rate main contributor decrease group effective tax rate compare low average expect tax rate discuss increase equity compensation plan tax benefit lower state tax impact item partially offset increase nondeductible expense low research development tax credit impact nondeductible expense increase mainly newly introduce brand pharmaceutical product fee impact equity compensation plan effective tax rate decrease increase mainly increase price underlie equity change state tax legislation result low state tax rate compare income tax benefit record respect equity compensation plan vary accord price underlie equity million swiss franc million swiss franc income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately million swiss franc million swiss franc record roche group note roche group consolidate financial statement roche finance report tax effect comprehensive income millions chf pretax tax aftertax pretax tax aftertax benefit benefit availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer income taxis asset liability net defer income tax asset liability movement amount record balance sheet current income taxis show table current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay charge credit income statement current income taxis adjustment recognise current tax prior period charge credit equity equity compensation plan transaction shareholder currency translation effect net current income tax asset liability december roche finance report roche group note roche group consolidate financial statementsdeferred income tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable mchf tax rate mchf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer income tax liability establish withholding tax taxis payable unremitted earning foreign subsidiary amount currently regard permanently reinveste total unremitted earning group billion swiss franc december billion swiss franc movement amount record balance sheet defer income taxis show table defer income taxis movement recognise net asset liability millions chf property plant equipment temporary intangible asset difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december roche group note roche group consolidate financial statement roche finance report business combination acquisition pvt effective april group acquire control interest privately own company pvt probenverteiltechnik gmbh base waiblingen germany pvt lab system llc base atlanta georgia united states jointly pvt pvt global market leader provide customise automation workflow solution vitro diagnostic testing large commercial hospital laboratory pvt report diagnostic operating segment acquisition complement strengthen group portfolio clinical diagnostic market purchase consideration pvt probenverteiltechnik gmbh million euro million euro pay cash million euro arise contingent consideration arrangement purchase consideration pvt lab system llc million dollar pay cash contingent payment arrangement base achievement performancerelate milestone arise end range outcome undiscounte million euro liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect closing balance sheet foreign exchange rate mtm laboratory effective august group acquire control interest privately own mtm laboratories mtm laboratory base heidelberg germany mtm laboratory develop vitro diagnostic detection diagnosis cancer focus cervical cancer early detection mtm laboratory report diagnostic operating segment acquisition complement group portfolio offer cervical cancer testing roche tissue diagnostic business total purchase consideration million euro million euro pay cash million euro arise contingent consideration arrangement contingent payment arrangement base achievement milestone arise range outcome undiscounte zero million euro liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect closing balance sheet foreign exchange rate anadys pharmaceutical effective november group acquire control interest anadys pharmaceuticals inc anadys publicly own company base san diego california prior acquisition anadys list nasdaq symbol ands anadys develop oral small molecule therapeutic potential treatment hepatitis virus hcv infection report roche pharmaceutical operating segment acquisition augment group hcv portfolio total purchase consideration million dollar pay cash combine purchase consideration million swiss franc consist million swiss franc cash million swiss franc contingent consideration arrangement allocate show table acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use marketing intangible inventory defer income taxis cash net asset liability net identifiable asset liability goodwill purchase consideration roche finance report roche group note roche group consolidated financial statementsgoodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc directly attributable transaction cost million swiss franc incur acquisition report general administration expense current period operating result roche pharmaceutical diagnostic operating segment million swiss franc million swiss franc respectively acquisition impact result million chf revenue inventory amortisation external fair value intangible operating customer adjustment asset profit net income impact report result anadys pharmaceutical division pvt mtm laboratory diagnostic division group estimate impact result acquisition assume effective january anadys pharmaceutical division pvt mtm laboratory diagnostic division group figure exclude directlyattributable transaction cost refer addition exclude integration cost million swiss franc relate acquisition diagnostic division correspond tax impact exclude acquisition net cash outflow millions chf cash cash net cash consideration pay acquire company outflow acquisition contingent consideration pay prior year acquisition total future acquisition december group announce enter agreement acquire control interest verum diagnostica gmbh verum purchase consideration million euro cash million euro contingent consideration arrangement base munich germany verum privately hold company specialise coagulation diagnostic focus platelet function test rapidly grow field coagulation market acquisition verum allow group gain market share coagulation segment strengthen lead position clinical diagnostic market transaction close effective january verum report diagnostic operating segment initial accounting transaction complete date consolidate financial statement approve issue board director january disclosure include fair value net asset acquire roche group note roche group consolidate financial statement roche finance report acquisition marcadia effective december group acquire control interest marcadia biotech inc marcadia privately own company base carmel indiana marcadia biopharmaceutical company focus develop broad portfolio drug candidate treatment diabete obesity marcadia report roche pharmaceutical operating segment total purchase consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement payment arrangement base achievement separate performance milestone arise range outcome undiscounte zero million dollar liability million swiss franc recognise acquisition date base management well estimate probability adjust expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect closing balance sheet foreign exchange rate accounting marcadia acquisition provisional end finalise half adjustment provisional acquisition accounting report annual financial statement medingo effective group acquire control interest medingo ltd medingo majority own subsidiary elron group base israel medingo engage development semidisposable insulin patch pump report diagnostic operating segment total purchase consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement payment arrangement base achievement separate performance milestone arise range outcome undiscounte zero million dollar liability million swiss franc recognise acquisition date base management good estimate probabilityadjuste expect cash outflow arrangement december recognise arrangement million swiss franc base recent management estimate reflect payment closing balance sheet foreign exchange rate bioimagene effective september group acquire control interest bioimagene inc bioimagene privately own company base sunnyvale california bioimagene engage digital pathology workflow analysis field report diagnostic operating segment total purchase consideration million dollar cash minor business combination diagnostic business total purchase consideration million swiss franc cash combine purchase consideration million swiss franc consist million swiss franc cash million swiss franc contingent consideration arrangement allocate show table acquisition net asset acquire millions chf carry value fair value carry value prior acquisition adjustment acquisition property plant equipment intangible asset product intangible use product intangible available use technology intangible use inventory defer income taxis cash net asset liability net identifiable asset liability goodwill purchase consideration roche finance report roche group note roche group consolidated financial statementsgoodwill represent control premium synergy obtain group exist business goodwill recognise expect deductible income tax purpose fair value net asset liability include receivables fair value million swiss franc directly attributable transaction cost million swiss franc incur acquisition report general administration expense current period operating result roche pharmaceutical diagnostic operating segment million swiss franc acquisition net cash outflow millions chf cash cash net cash consideration pay acquire company outflow acquisition total contingent consideration arrangement group party certain contingent consideration arrangement arise previous business combination arrangement provision arrangement record provision note set table provision discount time value money material provision contingent consideration arrangement millions chf january additional provision create unused amount reverse utilise year unwind discount business combination pvt mtm laboratories marcadia medingo minor business combination currency translation effect december expect outflow resource year year year year total roche group note roche group consolidate financial statement roche finance report global restructuring plan operational excellence november group announce detail concern operational excellence global restructuring plan plan aim adapt cost structure increasingly challenge market environment achieve significant efficiency productivity gain plan measure enable sustained investment research product development strengthen group longterm innovation capability effective june group complete sale site palo alto california party consideration million swiss franc cash million swiss franc pay result gain million swiss franc record general administration expense closure transfer research development activity roche site palo alto complete end subsidiary roche palo alto llc retain certain residual obligation divest group complete divestment certain subsidiary operational excellence programme effective august group complete sale manufacturing site boulder colorado consideration include certain contingent consideration arrangement base future performance site june net asset sell boulder consider disposal group write fair value cost sell result impairment charge million swiss franc charge general administration expense half million swiss franc relate property plant equipment majority residual inventory second half loss million swiss franc recognise disposal effective october group sell research development site madison wisconsin include select research asset consideration include equity stake contingent consideration arrangement base future achievement specify research development project milestone second half group divest research site kulmbach germany small property philippine total consideration receive subsidiary divestment million swiss franc consist million swiss franc cash marketable security fair value million swiss franc defer cash consideration million swiss franc receive total loss divestment subsidiary million swiss franc include general administration expense roche pharmaceutical operating segment group announce divest chemical production facility florence south carolina give unfavourable market chemical production asset group expect future capacity requirement small molecule group currently anticipate restructure activity substantially complete end total cost expect order billion swiss franc include billion swiss franc incur billion swiss franc incur roche finance report roche group note roche group consolidate financial statementsoperational excellence restructuring cost millions chf employeerelate cost termination cost pension postemployment benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost divestment product business impairment net assetsheldforsale gain loss divestment subsidiary total cost divestment product business impairment intangible asset reorganisation expense total classification operational excellence restructuring cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale roche pharmaceutical diagnostic marketing distribution roche pharmaceutical diagnostic research development roche pharmaceutical diagnostic general administration roche pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche group note roche group consolidate financial statement roche finance report genentech transaction restructuring integration july group announce offer purchase outstanding share genentech follow closing transaction genentech south san francisco site headquarters group combine pharmaceutical operation united states july group announce roche pharmaceutical business close manufacturing operation site nutley new jersey commercial operation move genentech research site palo alto california closed research activity transfer nutley genentech subsequent announcement initial restructuring activity start nutley palo alto site genentech transaction complete effective march follow pharmaceutical division initiate detailed integration programme align genentech business rest roche pharmaceutical business restructuring activity complete end genentech transaction restructure integration cost millions chf employeerelate cost termination cost pension postemployment benefit retention plan employee benefit employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment site closure cost total site closure cost reorganisation expense total employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan termination cost operational excellence genentech transaction restructure integration employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration roche finance report roche group note roche group consolidated financial statementsother employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit charge employee benefit operating result include relevant expenditure line function expect return plan asset interest cost define benefit plan include financial income financing cost respectively note pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group long term financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund administer party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly comprehensive income recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly comprehensive income roche group note roche group consolidate financial statement roche finance report define benefit plan expense millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement funding group define benefit plan oversee corporate level qualified independent actuary carry valuation regular basis major plan annually report date fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan amount recognise balance sheet postemployment benefit predominantly noncurrent report non current asset liability define benefit plan fund status millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report define benefit plan reimbursement right postemployment benefit asset postemployment benefit liability net recognise asset liability roche finance report roche group note roche group consolidated financial statementsfurther detailed information plan asset define benefit obligation give define benefit plan fair value plan asset reimbursement right millions chf fair value reimburse fair value reimburse plan asset ment right total plan asset ment right total january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost divestment subsidiary curtailment settlement december invest share equity instrument bond debenture debt instrument property asset total include fair value plan asset group share group share thousand group nonvoting equity security fair value million swiss franc thousand group nonvoting equity security fair value million swiss franc include debt instrument issue group fair value million swiss franc asset consist mainly cash special bond equity fund alternative mortgage commodity insurance policy roche group note roche group consolidate financial statement roche finance report define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost divestment subsidiary curtailment settlement december fund plan unfunded plan actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate return investment salary benefit level inflation rate cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity mortality table major scheme germany heubeck table japan national census life table switzerland bvg generational table pensioner bvg project nonpensioner united kingdom nonpensioner snal table rate year male year female future improvement medium cohort underpin united kingdom pensioner snal table rate year future improvement medium cohort underpin united states project rate employee turnover disability early retirement base historical behaviour group company roche finance report roche group note roche group consolidate financial statementsfinancial assumption base market expectation period obligation settle range assumption actuarial valuation significant plan country stable currency interest rate show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate calculate discount present value define benefit obligation determine reference market yield highquality corporate bond government bond countrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement calculate multiply discount rate define benefit obligation define benefit plan sensitivity discount rate millions chf current service cost interest cost define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis administration cost bear plan base longterm market expectation actual performance continually monitor corporate management longterm nature obligation assumption matter return investment necessarily consistent recent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference expect return actual return twelvemonth period actuarial gainloss record directly comprehensive income actual return plan asset gain million swiss franc gain million swiss franc expect rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance roche group note roche group consolidate financial statement roche finance report medical cost trend rate calculate define benefit obligation current service cost include income statement postemployment medical plan account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation funding summary fiveyear summary funding status group define benefit plan show table define benefit plan summary funding status millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation increase decrease funding status arise experience adjustment fair value plan asset define benefit obligation increase decrease funding status arise change actuarial assumption fair value plan asset define benefit obligation cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution benefit pay unfunded plan estimate approximately million swiss franc roche finance report roche group note roche group consolidated financial statementsamount record comprehensive income actuarial gain loss recognise statement comprehensive income loss million swiss franc loss million swiss franc pretax total december accumulate loss million swiss franc accumulate loss million swiss franc addition recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit asset recognition record directly comprehensive income adjustment decrease million swiss franc decrease million swiss franc employee stock option equity compensation plan group operate equity compensation plan include separate plan chugai effective january group adopt ifrs sharebased payment matter standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement heading expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense share option plan roche option plan chugai stock acquisition right total share option plan equity compensation plan bonus stock award roche connect roche stocksettle stock appreciation right roche restrict stock unit plan chugai retirement stock acquisition right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle roche group note roche group consolidate financial statement roche finance report cash inflow outflow equity compensation plan millions chf equitysettle equity compensation plan roche option plan exercise chugai stock acquisition right exercise roche connect cost total equitysettle equity compensation plan cash outflow transaction equity instrument total cash inflow outflow equitysettle equity compensation plan net transaction equity instrument cashsettle plan include movement net work capital roche stock appreciation right net cash outflow transaction equity instrument arise sale purchase nonvoting equity security genussscheine derivative instrument thereon hold group potential conversion obligation arise group equitysettle equity compensation plan derivative instrument mainly consist option exercisable time maturity note roche longterm group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan follow integration genentech group establish restrict stock unit rsu plan award plan september employee genentech ssar issue accordance roche ssar plan regulation january include amendment effective january addenda include roche ssar plan addendum united states september remuneration committee determine number nonvoting equity security genussscheine available plan year regulation collectively provide million nonvoting equity security genussscheine available issuance roche ssar plan tenyear period rsus issue accordance roche restrict stock unit plan regulation effective september million nonvoting equity security genussscheine available issuance tenyear period detail plan give relevant section share option plan roche option plan award plan employee right purchase nonvoting equity security genussscheine exercise price specify grant date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche finance report roche group note roche group consolidated financial statementsroche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total chugai stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price right nontradable equitysettle award tenyear duration vest year chugai stock acquisition right movement number right outstanding weighted average weight average number exercise price number exercise price right jpy right jpy outstanding january grant forfeit exercise expired outstanding december exercisable roche group note roche group consolidate financial statement roche finance report chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted average weighted average weight average number year remain exercise price number exercise price year grant outstanding contractual life jpy exercisable jpy award total issue share option issue share option include methodology calculate fair value main input valuation model describe issue share option plan roche chugai stock option plan acquisition right number option grant underlying equity roche nonvoting equity security chugai share block currency swiss franc japanese yen vest period progressively year year contractual life year year weight average fair value option issue option pricing model binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor expect exit rate volatility roche chugai option determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche finance report roche group note roche group consolidated financial statementsexercise share option weight average share price roche nonvoting equity security genussscheine date exercise roche option plan option swiss franc share option chugai share underlie equity exercise year equity compensation plan bonus stock award bonus member corporate executive committee award form immediately vest nonvoting equity security genussscheine total award issue total fair value million swiss franc fair value award calculate basis market value roche nonvoting equity security grant date roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security genussscheine administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary non vote equity security directly market december administrator hold million nonvoting equity security million programme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function roche stocksettle stock appreciation right introduction roche longterm group offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security genussscheine reflect value appreciation market price nonvoting equity security grant date exercise date right nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase non vote equity security derivative thereon note roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche group note roche group consolidate financial statement roche finance report roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total weight average fair value right grant calculate binomial model input model consistent roche option plan award give previously expect volatility result weight average fair value right swiss franc give total fair value million swiss franc charge vest period year roche restrict stock unit plan time september group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity security genussscheine vest threeyear period weight average fair value award grant swiss franc calculate basis market value roche nonvoting equity security date issue discount account award accrue dividend vest period roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december exercisable chugai retirement stock acquisition right time chugai issue stock acquisition right lieu retirement gratuity system director abolish right issue thirtyyear duration vest holder retirement director chugai right entitle holder purchase chugai share exercise price japanese yen total fair value right issue equivalent million swiss franc million swiss franc calculate binomial model input consistent chugai stock appreciation right give previously roche finance report roche group note roche group consolidated financial statementsroche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager programme establish beginning currently operate annual threeyear cycle term currently outstanding award set table nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate valuation take account define rank performance structure determine payout plan roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar nontradable cashsettle award exercise vest period year cash payment base market price group american depositary receipt adr point exercise exceed strike price grant price issuance follow implementation roche longterm group award cashsettle sar award roche stock appreciation right millions chf liability december intrinsic value vest right december outstanding award end roche group note roche group consolidate financial statement roche finance report property plant equipment property plant equipment movement carry value asset millions chf building machinery land construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal business combination transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal business combination divestment subsidiary transfer reclassification assetsheldforsale depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value roche finance report roche group note roche group consolidate financial statementsimpairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment impairment charge million swiss franc million swiss franc report cost sale million swiss franc million swiss franc research development impairment charge report general administration million swiss franc income million swiss franc receive insurance company respect impairment property plant equipment respect damage arise east japan earthquake note borrowing cost capitalise property plant equipment million swiss franc rate leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method roche group note roche group consolidate financial statement roche finance report finance lease future minimum lease payment noncancellable lease millions chf present value future gross investment lease minimum lease payment year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc roche finance report roche group note roche group consolidated financial statement goodwill goodwill movement carry value asset millions chf january business combination divestment subsidiary impairment charge currency translation effect december allocate follow cashgenerating unit pharmaceutical division roche pharmaceutical chugai total pharmaceutical division diagnostic division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic strategic goodwill hold divisional level allocate business area total diagnostic division accumulate impairment loss goodwill goodwill arise investment associate classify investment associate note goodwill impairment testing pharmaceutical division division subdivision cashgenerate unit test goodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model datum swiss capital market include swiss federal government twentyyear bond swiss market index weight average tax rate calculation correspond pretax discount rate management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable roche group note roche group consolidate financial statement roche finance report diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year estimate tissue diagnostic business area project year management believe reflect longterm nature business valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model datum swiss capital market include swiss federal government twentyyear bond swiss market index weight average tax rate calculation correspond pretax discount rate management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group roche finance report roche group note roche group consolidate financial statementsintangible asset movement carry value asset continue millions chf product product intangible marketing technology intangible available intangible intangible use use use use total year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use tanox acquisition roche pharmaceutical year corangeboehringer mannheim acquisition diagnostic year ventana acquisition diagnostic year product intangible available use intermune alliance roche pharmaceutical ventana acquisition diagnostic classification amortisation impairment expense millions chf amortisation impairment amortisation impairment cost sale pharmaceutical diagnostic marketing distribution diagnostic research development pharmaceutical diagnostic total roche group note roche group consolidate financial statement roche finance report internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful life impairment intangible asset impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment roche pharmaceutical operating segment record impairment charge million swiss franc diagnostic operating segment record impairment charge million swiss franc pharmaceutical operating segment impairment charge million swiss franc record related decision stop development project acquire business combination outlicense alliance partner asset concern partly amortise write recoverable value million swiss franc base value use calculation aftertax discount rate charge million swiss franc record result portfolio prioritisation decision project acquire separately business combination asset concern amortise fully write charge diagnostic operating segment impairment charge million swiss franc record mainly respect intangible asset use follow regular updating division business plan technology assessment second half asset concern write recoverable million swiss franc base value use calculation aftertax discount rate roche pharmaceutical operating segment record impairment charge million swiss franc diagnostic operating segment record impairment charge million swiss franc record roche pharmaceutical operating segment impairment charge million swiss franc record operational excellence programme note programme division carry comprehensive portfolio review decide discontinue certain activity research early development addition certain product development activity discontinue transfer roche site party result decision intangible asset carry value million swiss franc fully write apart operational excellence programme impairment charge million swiss franc record pharmaceutical division respect product intangible available use follow primarily recent clinical datum portfolio prioritisation decision relate certain project alliance partner acquire business combination asset concern amortise fully write charge charge million swiss franc record result portfolio prioritisation decision project acquire previous business combination asset concern amortise write recoverable value million swiss franc base value use calculation aftertax discount rate reversal previously record impairment loss million swiss franc record follow late clinical datum assessment project concern diagnostic operating segment impairment charge million swiss franc record respect intangible asset use follow regular updating division business plan technology assessment second half asset concern write recoverable million swiss franc base value use calculation aftertax discount rate roche finance report roche group note roche group consolidate financial statementsintangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december carry value asset pharmaceutical division million swiss franc approximately represent project potential decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project question result commercialise product potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure undiscounted risk adjust meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total associate group investment associate account equity method goodwill arise investment associate classify investment associate investments associate millions chf share net income carry value total investment associate group significant investment associate material transaction group associate additional information associate give note roche group note roche group consolidate financial statement roche finance report financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset longterm employee benefit total longterm asset financial longterm asset hold strategic purpose classify noncurrent availableforsale investment mainly equity investment primarily investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably carry value equity investment hold cost million swiss franc million swiss franc million swiss franc loan receivable comprise loan party term year inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc million swiss franc roche finance report roche group note roche group consolidated financial statement account receivable account receivable million chf trade account receivable note receivable allowance doubtful account chargeback allowance total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc billion swiss franc allowance doubtful account receivable movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december expense relate bad debt expense marketing distribution total million swiss franc million swiss franc significant concentration trade receivables counterparty credit risk described note second half group accept offer greek government settle billion euro trade receivable nominal value zero coupon government bond redeemable settlement term imply discount million euro average discount additional allowance doubtful account total million swiss franc respect bond deliver point carry value trade receivables net accumulate allowance doubtful account reclassify availableforsale marketable security allowance utilise respect total million swiss franc subsequently group sell vast majority bond total financial result trade receivables zero coupon bond scope settlement expense million swiss franc include interest income gain loss sale bond impairment remain position market value december roche group note roche group consolidate financial statement roche finance report current asset current asset millions chf accrue interest income derivative financial instrument restrict cash total financial current asset prepaid expense total nonfinancial current asset total current asset derivative financial instrument asset primarily relate hedge nonus dollardenominated bond note issue finance genentech transaction decline compare december mainly strengthen dollar compare euro marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss bond debenture total financial asset fairvaluethroughprofitorloss heldtomaturity financial asset money market instrument time account month total heldtomaturity financial asset availableforsale financial asset share bond debenture money market instrument time account month investment total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc dollar euros investment hold strategic purpose classify noncurrent note share consist primarily readily saleable equity security bond debenture carry value contract maturity debt security show roche finance report roche group note roche group consolidated financial statementsbond debenture millions chf contract maturity year year year total bond debenture money market instrument contract mature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent account payable account payable million chf trade account payable taxis payable dividend payable account payable total account payable accrue current liability accrue liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability roche group note roche group consolidate financial statement roche finance report derivative financial instrument group use derivative financial instrument risk management activity discuss note derivative financial instrument carry fair value method determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk manage derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe cash flow hedge group issue bond note finance genentech transaction note bond note denominate euros sterling group enter crosscurrency swap hedge foreign exchange interest rate risk cash flow hedge qualify hedge accounting december instrument designate qualify hedge accounting record asset fair value million swiss franc asset million swiss franc ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table decline expect cash flow strong swiss franc euro dollar pound sterle roche finance report roche group note roche group consolidated financial statementsexpected cash flow qualify cash flow hedge millions chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total undiscounted cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity decline expect cash flow strong swiss franc euro dollar pound sterling expect cash flow qualify cash flow hedge impact profit loss million chf total month month month year year year year year year end december cash inflow cash outflow total year end december cash inflow cash outflow total change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument instrument designate qualified fair value hedge record balance sheet december asset fair value million swiss franc gain million swiss franc record interest rate swap fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument similar transaction interest rate swap expire july underlie bond redeem loss million swiss franc record interest rate swap fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record liability fair value million swiss franc liability million swiss franc loss million swiss franc record forward contract loss million swiss franc result forward contract offset change fair value hedge equity investment group use derivative designate qualify hedge relationship manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forward contract option roche group note roche group consolidate financial statement roche finance report provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise year unwind discount business combination acquire company contingent consideration currency translation effect december current portion noncurrent portion total provision year end december january additional provision create unused amount reverse utilise year unwind discount business combination acquire company contingent consideration contingent consideration utilisation divestment subsidiary currency translation effect december current portion noncurrent portion total provision expect outflow resource year year year year total provision roche finance report roche group note roche group consolidate financial statementslegal provision legal provision consist number separate legal matter include claim arise trade group company majority cash outflow matter expect occur year dependent development litigation significant provision discount time value money material environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict estimate timing cash outflow show table significant provision discount time value money material restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain global basis show table provision discount time value money material matter employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance show table significant provision discount time value money material provision provision relate sale return provision group company fit category timing cash outflow nature uncertain good estimate show table significant provision discount time value money material contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action involve approximately plaintiff bring federal state court united states personal injury allegedly result use accutane action allege ibd result accutane use june hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product united states roche group note roche group consolidate financial statement roche finance report action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation united states district court middle district florida tampa division july district court grant summary judgment favour hlr lead federal ibd case plaintiff appeal august ruling affirm united states court appeal eleventh circuit october district court grant summary judgment favour hlr federal ibd case plaintiff appeal november ruling affirm united states court appeal eleventh circuit multiple recently file matter remain pende action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar verdict reverse appeal retrial result verdict favour plaintiff assess total compensatory damage million dollar hlr currently process posttrial briefing second verdict million dollar reverse appeal new jersey supreme court accept hlrs petition certification review decision superior court new jersey appellate division trial remain pende hlr appeal verdict involve plaintiff superior court new jersey appellate division remain pende trial involve plaintiff try superior court jury reach defence verdict case award compensatory damage million dollar case case posttrial brief additional trial commence november result mistrial jury reach verdict trial involve plaintiff schedule october jury circuit court escambia county florida return verdict favour plaintiff assess total compensatory damage million dollar subsequently reduce million dollars court company october district court appeal state florida reverse enter judgment hlr supreme court florida decline review plaintiff appeal additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim cabilly patent october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk file patent lawsuit genentech city hope district court southern district florida lawsuit relate patent cabilly patent coowne genentech city hope lawsuit seek declaratory judgment patent invalidity unenforceability regard cabilly patent patent noninfringement regard certain gsk product december genentech file motion dismiss alternative transfer central district california gsk dismiss florida lawsuit entirety february file related action day northern district california genentech file motion transfer central district california answer counterclaim gsk march april genentech motion transfer grant february court issue claim construction order construe certain term claim cabilly patent summary judgment motion file january additional lawsuit genentech gsk andor human genome sciences inc hgs involve cabilly patent relate patent cabilly iii patent pende district court central district california proceeding case stay additional lawsuit include claim gsk andor hgs cabilly patent infringe invalid unenforceable genentech violate antitrust unfair competition law law outcome matter determine time roche finance report roche group note roche group consolidated financial statementsrituxan arbitration sanofihoechst october genentech biogen idec inc file complaint sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc northern district california seek declaratory judgment certain genentech product include rituxan infringe sanofis patent declaratory judgment patent invalid october sanofi file suit genentech biogen idec eastern district texas lufkin division claim rituxan genentech product infringe patent sanofi bring claim preliminary permanent injunction compensatory exemplary damage relief genentech challenge venue texas case opinion federal circuit court appeals texas california case consolidated northern district california district court issue claim construction order june sanofi file motion reconsideration deny genentech biogen idec file motion summary judgment sanofi oppose court hear motion november march rule matter law genentech biogen idec infringe assert patent claim sanofi file notice appeal court noninfringement rule claim construction order appeal pende addition october hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate agreement hoechst predecessor genentech pertain patent relate patent outside united states hoechst seek payment royaltie sale genentech product damage breach contract relief icc arbitration hearing hold august september june arbitrator issue intermediate decision indicating rituxan cover terminate agreement order genentech produce certain rituxan sale information december october group expect arbitrator use information ascertain damage award hoechst group record expense million swiss franc net assume reimbursement portion group obligation copromotion partner biogen idec record cost sale royalty expense correspond increase accrue liability balance sheet amount accrue represent management well estimate compensatory damage include interest award hoechst base financial term terminate agreement final decision vary amount provide nature andor extent damage award hoechst differ group estimate genentech successfully challenge arbitrator decision july genentech file declaration appeal court appeal paris initiate legal proceeding challenge arbitrator decision arbitrator subsequently state party june decision decide operative underlie issue liability respect rituxan light statement genentech pursue previously file action challenge arbitrator decision prejudice ability bring challenge future genentech anticipate substantially complete briefing liability owe license agreement arbitrator find liability march hearing issue currently schedule april outcome matter determine time rituxan investigation october genentech receive subpoena united states department justice request document relate promotion rituxan genentech cooperate government associate investigation previously investigation civil criminal nature genentech inform august criminal prosecutor handle matter government decline prosecute genentech criminally connection investigation civil matter ongoing counsel genentech continue discussion government representative status investigation genentech view matter include potential resolution october government notify genentech decide civil claim genentech government investigation initiate complaint file seal district court eastern district pennsylvania individual plaintiff complaint unseal december basis civil litigation plaintiff roche holdings inc genentech follow settlement discussion plaintiff genentech government agree settlement claim approximately million dollar court enter order dismissing case november roche group note roche group consolidate financial statement roche finance report average wholesale price litigation hlr roche laboratories inc rli genentech approximately brand generic pharmaceutical company name defendant legal action united states relate pricing pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresented report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend action file follow states alabama mississippi new jersey kansas louisiana genentech defend action file state kansas discovery currently pende case hlr rli genentech intend vigorously defend matter outcome matter determine time brand prescription drug litigation hlr brand pharmaceutical company name defendant legal action united states bring retail pharmacy relate discount practice brand prescription drug bnpd bnpd litigations plaintiff allege deny discount certain prescription drug offer mail order manage care entity denial claim violation robinsonpatman act rpa rpa federal law prohibit unlawful price discrimination addition plaintiff allege defendant conspire refusal offer certain discount conspiracy claim defendant previously settle rpa claim remain litigate december hlr defend approximately bnpd action bring federal state court united states discovery currently pende case hlr currently schedule trial bnpd matter hlr intends vigorously defend outcome matter determined time intermune litigation june august september genentech name defendant intermune inc chief executive officer scott harkonen separate classaction complaint file district court northern district california behalf plaintiff allegedly pay purchase price product license genentech connectic corporation subsequently assign intermune genentech respond complaint motion dismiss matter grant april plaintiff file amend complaint include state law claim genentech respond complaint motion dismiss hear september court grant genentech motion dismiss respect claim leave plaintiff replead specific claim california unfair competition law plaintiff file amend class action complaint december naming genentech defendant claim unfair competition law false advertising law consumer remedy law consumer protection law unjust enrichment genentech seek dismissal amend complaint september court enter order grant genentech motion dismiss claim prejudice plaintiff file appeal district court rule united states court appeals ninth circuit december court appeal affirm district court rule respect university pennsylvania litigation genentech file patent lawsuit university pennsylvania district court northern district california lawsuit relate united states patent seek declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seek unspecified damage base sale herceptin genentech file answer august court issue claim construction order construe certain term claim patent december university file motion summary adjudication certain fact order date january court set april hearing date motion trial currently set june outcome matter determine time roche finance report roche group note roche group consolidated financial statementspdl litigation august pdl biopharma pdl file complaint genentech nevada state court seek judicial declaration concern genentech obligation pay royalty certain exus sale herceptin avastin xolair lucentis agreement party september pdl file amend complaint assert additional claim genentech include breach contract breach imply covenant good faith fair dealing pdl assert new claim roche novartis intentional interference contractual relation addition declaratory relief pdl seek monetary damage include liquidate punitive damage november genentech roche file motion dismiss failure state claim roche file additional motion dismiss lack personal jurisdiction court deny motion july outcome matter determine time gsk litigation september gsk genentech file patent lawsuit case gsk roche holding ltd district court district delaware northern district california respectively lawsuit concern gsk patent nos gsk assert claim genentech roche allege infringement patent certain therapeutic antibody product complaint specifically refer herceptin lawsuit genentech seek judicial declaration noninfringement certain genentech product delaware action november genentech file motion dismiss failure state claim motion transfer case california roche file motion dismiss lack personal jurisdiction join genentech motion event personal jurisdiction motion deny party subsequently stipulate roche dismissal genentech remain party motion transfer case california remain pende california action december court enter order stay california action pende resolution delaware court genentechs motion transfer outcome matter determine time boniva litigation hlr roche affiliate name defendant numerous legal action united states canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw onj atypical femoral fracture december hlr defend approximately action bring federal state court united states action bring court queen bench province saskatchewan canada personal injury allegedly result use boniva case early discovery stage litigation case set trial december individual trial result depend variety factor include unique particular case hlr name roche affiliate intend vigorously defend matter outcome matter determined time diagnostic legal case marsh supermarket litigation july marsh supermarkets inc marsh file breach contract suit roche diagnostic operation inc rdo lawsuit relate termination sublease agreement building rdo extensive argument bench trial hamilton superior court judge award marsh damage amount million dollar accrue legal provision rdo intend appeal judgment outcome appeal determine time roche group note roche group consolidate financial statement roche finance report noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability consist mainly accrue longterm employee benefit debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt gain loss redemption repurchase bond note net amortisation debt discount foreign currency transaction gain loss net currency translation effect december consist bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt report longterm debt shortterm debt total debt fair value bond note billion swiss franc billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt roche finance report roche group note roche group consolidated financial statementsbond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note float rate month libor note february principal billion dollar note february principal million dollar dollardenominated note fix rate note march principal billion dollar note march principal billion dollar outstanding billion dollars isin usual usaq note march principal billion dollars isin usuam usas note march principal billion dollars isin usuan usau european medium term note programme float rate month euribor note march principal billion euro european medium term note programme fix rate note march principal billion euro outstanding billion euro isin note march principal billion pound sterle outstanding billion pound sterling isin note march principal billion euro isin note march principal billion euro isin note august principal million pound sterle outstanding million pound sterling isin swiss franc bond bond march principal billion swiss franc outstanding billion swiss franc isin bond march principal billion swiss franc isin genentech senior note senior note july principal million dollar senior note july principal billion dollar isin usag senior note july principal million dollar isin usac total roche group note roche group consolidate financial statement roche finance report bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note group issue bond note redemption repurchase bond note redemption dollardenominated note date february group redeem note principal million dollar original issue plus accrue original issue discount oid effective interest rate note months libor plus cash outflow million swiss franc gain loss record redemption partial early redemption dollardenominated note december group resolve exercise option redemption portion dollardenominate fix rate note march group redeem billion dollar total principal billion dollar note march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrued interest december group revise carry value note account change amount timing estimate cash flow increase carry value million swiss franc record financing cost additional loss million swiss franc incur final settlement note effective interest rate note partial repurchase eurodenominate note june group complete tender offer nominal million euro fix rate note march total principal billion euro cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc addition group terminate currency swap hedge foreign currency risk eurodenominate note create additional loss million swiss franc reflect change fair value hedge derivative change interest rate total loss repurchase million swiss franc record financing cost note effective interest rate note repurchase roche finance report roche group note roche group consolidate financial statementspartial repurchase swiss francdenominate bond november group complete tender offer nominal million swiss franc fix rate bond march total principal billion swiss franc cash outflow million swiss franc plus accrued interest loss repurchase bond million swiss franc effective interest rate bond repurchase partial repurchase pound sterlingdenominate note december group complete tender offer nominal million pound sterling fix rate note march total principal billion pound sterle cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc effective interest rate note repurchase partial repurchase pound sterlingdenominate note december group complete tender offer nominal million pound sterling fix rate note august total principal million pound sterle cash outflow million swiss franc plus accrued interest loss repurchase note million swiss franc effective interest rate note repurchase redemption repurchase bond note redemption dollardenominated note date february group redeem note principal billion dollar original issue plus accrue original issue discount oid effective interest rate note months libor plus cash outflow million swiss franc gain loss record redemption redemption european medium term note programme note date march group redeem note principal billion euro original issue plus accrue original issue discount oid effective interest rate note month euribor plus plus include hedge cash outflow million swiss franc gain loss record redemption redemption genentech senior note date july group redeem note principal million dollar original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record redemption early redemption dollardenominated note june group resolve exercise option redemption dollardenominate fix rate note march principal billion dollars group redeem note september equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal effective interest rate note redemption cash outflow million swiss franc plus accrued interest loss redemption million swiss franc record financing cost note cash outflow redemption repurchase bond note millions chf dollardenominated note european medium term note programme eurodenominate note european medium term note programme pound sterlingdenominate note swiss franc bond genentech senior note total cash outflow redemption repurchase bond note roche group note roche group consolidate financial statement roche finance report collateral arrangement group enter currency swap certain nonus dollar debt instrument issue collateral agreement enter counterpartie currency swap mitigate counterparty risk total billion swiss franc cash collateral deliver group billion swiss franc deliver group collateral receive record increase cash correspond increase accrue liability carry value accrue liability respect agreement december billion swiss franc december accrue liability billion swiss franc commercial paper roche holdings inc commercial paper program march roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro available backstop line maturity note program exceed day date issuance december unsecured commercial paper note principal million dollar average interest rate outstanding amount date march movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency notably chinese renminbi argentine peso average interest rate average interest rate balance primarily denominate taiwanese dollar repayment date year million swiss franc million swiss franc year roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest movement december amount transfer income statement gain million swiss franc report royalty operate income loss million swiss franc financial income roche group note roche group consolidate financial statement roche finance report change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment valuation gain loss take equity transfer income statement sale impairment income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment noncontrolle interest define benefit postemployment plan actuarial gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity instrument change noncontrolle interest december entire loss transfer income statement million swiss franc report financial income group complete purchase noncontrolle interest genentech effective march base revise international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statementsshare capital december authorise issue share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security december december millions millions nonvoting equity security derivative instrument total equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number non vote equity security market value millions maturity strike price chf chf billion nonvoting equity security derivative instrument feb sep total roche group note roche group consolidate financial statement roche finance report nonvoting equity security derivative instrument hold group potential conversion obligation arise roche option plan roche stocksettle stock appreciation right roche restrict stock unit plan note mainly consist option exercisable time maturity group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share nonvoting equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise employee stock option plan exercise outstanding vested employee stock option dilutive effect exercise outstanding vested chugai stock option dilutive effect net income chugai positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure roche finance report roche group note roche group consolidated financial statementsdilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation define benefit postemployment plan comprehensive income net tax total comprehensive income dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity instrument change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest roche group note roche group consolidate financial statement roche finance report statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense associate financial income financing cost income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment intangible asset impairment property plant equipment impairment net assetsheldforsale operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan net income expense provision bad debt expense inventory writedown adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total roche finance report roche group note roche group consolidated financial statementscash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity significant noncash transaction significant noncash transaction risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management specifically describe detail financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai roche group note roche group consolidate financial statement roche finance report carry value fair value financial asset millions chf carry value asset class fvtpla available heldfor heldto loan line item note forsale trading maturity receivables total fair value year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total year end december account receivable accrue interest income marketable security money market instrument time account month bond debenture share investment cash cash equivalent derivative financial instrument availableforsale investment heldtomaturity investment loan receivable longterm trade receivables financial current asset restrict cash longterm asset total fairvaluethroughprofitorloss roche finance report roche group note roche group consolidated financial statementsfollowing implementation amendment ifrs financial instrument disclosure publish march group establish fair value hierarchy reflect significance input make fair value measurement fair value hierarchy include follow level level quote price active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture share derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total fair value hierarchy financial asset liability december millions chf level level level total financial asset recognise fair value marketable security money market instrument time account month bond debenture share derivative financial instrument availableforsale investment total financial liability recognise fair value derivative financial instrument total availableforsale investment exclude equity security hold cost million swiss franc million swiss franc carry fair value note december level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument unquoted share significant transfer level level vice versa roche group note roche group consolidate financial statement roche finance report change fair value level financial asset millions chf january impairment charge valuation gain loss take equity gain loss recognise income statement sale currency translation difference december credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset trade receivables subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective management trade receivables sustain growth profitability group optimise asset utilisation whilst maintain risk acceptable level note significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie additionally group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold loan receivables december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent december group combine trade account receivable public customer southern europe spain italy greece portugal equivalent billion swiss franc represent group consolidated trade account receivables billion swiss franc represent trade receivables spain italy portugal increase receivables greece decrease mainly settlement trade receivables zero coupon government bond redeemable group use different measure improve collection country include intense communication customer negotiation payment plan charge interest late payment legal action roche finance report roche group note roche group consolidated financial statementsthe nature geographic location counterpartie trade receivable overdue show table include overdue balance national wholesalers southern europe public customer describe trade receivables overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable security subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution fix income marketable security group hold billion swiss franc government security switzerland counterpartie rating well exception greece million swiss franc december greek government bond allocate bbb range relate settlement overdue receivables rating analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivative group sign net collateral agreement isda international swap derivative association master agreement respective counterpartie order mitigate counterparty risk derivative position group enter derivative contract party hedge foreign exchange risk arise bond note issue group affiliate roche holdings inc currencie dollar total exposure hedge issuance bond note approximately billion swiss franc note group return billion swiss franc strengthen dollar euro pound sterling total billion swiss franc cash collateral deliver group collateral agreement set cash acceptable collateral collateral received deliver december relate derivative activity roche group note roche group consolidate financial statement roche finance report overdue asset financial asset past impair total billion swiss franc billion swiss franc analysis overdue impair financial asset class millions chf total overdue month month month month year year end december loan receivables year end december loan receivables december financial asset term renegotiate liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time group liquidity report senior management monthly basis roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement addition group unused committed credit line financial institution total billion swiss franc billion swiss franc decline undiscounted financial liability show table mainly debt repayment interest pay contractual maturity analysis financial liability millions chf total month month month year year year year year year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability year end december total debt trade payable accrual derivative financial instrument liabilitie current noncurrent total financial liability total debt table show undiscounted cash flow carry value consolidate balance sheet reflect discount cash flow roche finance report roche group note roche group consolidated financial statementsmarket risk market risk arise change market price group financial asset financial liability market risk affect group financial result value group equity group use valueatrisk var measure impact market risk financial instrument roche define var limit manage market risk var datum report monthly basis indicate value range give financial instrument fluctuate preset probability result movement market price var statistical measure implicitly assume value change recent past indicative value change future var figure represent actual expect loss possible worstcase loss state period var figure calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate long hold period increase probability high value change lead increase var figure actual future gain loss associate treasury activity differ materially var analysis perform inherent limitation associate predict timing change interest rate foreign currency exchange rate equity investment price particularly period high market volatility furthermore var number include effect change credit spread market risk financial instrument millions chf december december var interest rate component var foreign exchange component var price component diversification var total market risk december total var financial asset liabilitie million swiss franc december million swiss franc interest rate var decrease million swiss franc reflect age debt repayment debt issue debt hold amortise cost interest rate var sole metric economic fair value change impact carry value profit loss group foreign exchange var increase slightly low diversification effect price risk arise mainly movement price equity security remain largely stable december group hold equity security market value billion swiss franc december billion swiss franc include holding biotechnology company acquire context licensing transaction scientific collaboration foreign exchange risk group operate world expose movement foreign currency affect group financial result value group equity foreign exchange risk arise local currency pay receive transaction denominate foreign currency vary change exchange rate transaction exposure foreign currency denominate financial statement group foreign subsidiary vary consolidation swiss francdenominate group financial statement translation exposure roche group note roche group consolidate financial statement roche finance report objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group currently hedge translation exposure financial instrument group monitor transaction exposure daily basis net foreign exchange result correspond var parameter report monthly basis group use forward contract foreign exchange option cross currency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity change interest rate cause variation interest income expense addition affect market value certain financial asset liability hedge instrument primary objective group interest rate management protect net interest result interest rate exposure correspond var parameter report monthly basis group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment equity price risk report var figure monthly basis senior management impairment financial asset impairment loan receivables mainly increase expect nonrecoverability trade receivables write down debt security million swiss franc relate greek government bond receive exchange trade receivable note impairment loss asset class millions chf loan receivables availableforsale financial asset share investment debt security total impairment loss roche finance report roche group note roche group consolidated financial statementscapital group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event group complete purchase noncontrolle interest genentech effective march consideration net tax effect approximately billion swiss franc base revised international accounting standard consolidated separate financial statement ias adopt group transaction account equity transaction consequence carrying consolidate equity group reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy capital monitor basis capitalisation calculate debt plus equity include non control interest report senior management group regular internal management reporting group capitalisation show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management roche group note roche group consolidate financial statement roche finance report relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri maja oeri jrg duschmal lukas duschmal march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition charitable foundation establish pool member admit pool pool consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive remuneration total swiss franc swiss francs oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel total remuneration key management personnel million swiss franc million swiss franc million swiss franc member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board director exclude chairman total million swiss franc million swiss franc million swiss franc chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee hippe oday soriot include table calendar year join cec similarly members corporate executive committee retire way year hunziker include calendar year leave cec roche finance report roche group note roche group consolidated financial statementsremuneration chairman board director member corporate executive committee millions chf salary include bonus expense bonusspecial stock award social security cost pension postemployment benefit equity compensation plan retirement awards employee benefit total purpose remuneration disclosure value equity compensation plan include bonus special stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include financial statement roche holding ltd basel page disclosure value equity compensation plan include special stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration chairman board director member corporate executive committee ifrs basis table deduct bonusspecial stock award ifrs basis equity compensation plan ifrs basis add bonusspecial stock award swiss legal basis equity compensation plan swiss legal basis total remuneration chairman board director member corporate executive committee swiss legal basis chairman board director member corporate executive committee bonusspecial stock award member corporate executive committee grant bonus stock award lieu cashsettle bonus financial year special stock award roche longterm member corporate executive committee grant stocksettle stock appreciation right ssar roche option plan rop restricted stock unit rsu award ssar rop rsu award roche group note roche group consolidate financial statement roche finance report roche connect contribution pay group respect chairman board director member corporate executive committee total million swiss franc million swiss franc roche performance share plan member corporate executive committee target award cycle awards cycle award result zero nonvoting equity security depend achievement performance target transaction member corporate executive committee pension tax consulting service total million swiss franc pay group corporate executive committee member million swiss franc member postemployment benefit plan transaction group postemployment define benefit plan employee group describe note subsidiary associate divestment subsidiary effective group sell wholly own subsidiary roche vitamins inc rvi party addition disclose note group complete sale follow whollyowne subsidiary connection operational excellence programme roche colorado corporation boulder colorado roche madison inc madison wisconsin roche kulmbach gmbh kulmbach germany lascona land company inc philippine total consideration receive divestment million swiss franc consist million swiss franc cash marketable security fair value million swiss franc defer cash consideration million swiss franc receive total gain loss divestment show table gain loss divestment subsidiary millions chf consideration net asset dispose property plant equipment goodwill provision cash net asset accumulate currency translation adjustment total net asset dispose transaction cost provision accrual residual obligation retain roche group gain loss divestment report global restructuring cost roche pharmaceutical operating segment general administration cost corporate operating segment roche finance report roche group note roche group consolidated financial statementsliste company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share isin genussschein market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy nonliste company share capital equity interest country company city millions argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium roche brussels eur roche diagnostic belgium brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche china hold shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica roche servicios heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd roche group note roche group consolidate financial statement roche finance report share capital equity interest country company city millions salvador productos roche salvador san salvador svc estonia roche eesti tallinn eur finland roche diagnostic espoo eur roche espoo eur france roche diagnostic france sas meylan eur roche sas boulognebillancourt cedex eur ventana medical systems illkirch eur germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories heidelberg eur roche pharma grenzachwyhlen eur roche pvt gmbh waiblingen eur swisslab gmbh berlin eur greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr mexico producto roche mexico city mxn roche servicios mxico mexico city mxn morocco roche casablanca mad netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama producto roche panam panama city pab producto roche interamericana panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf roche finance report roche group note roche group consolidate financial statementsshare capital equity interest country company city millions peru producto roche qumica farmacutica lima pen philippine roche philippines inc taguig city php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited illovo zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabete care burgdorf chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche glycart schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united kingdom pirame limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp roche group note roche group consolidate financial statement roche finance report share capital equity interest country company city millions united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc san diego usd bioveris corporation wilmington usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd marcadia biotech inc wilmington usd memory pharmaceuticals corp montvale usd roche carolina inc florence usd roche diagnostic corporation indianapoli usd roche diagnostic operation inc indianapoli usd roche holdings inc wilmington usd roche insulin delivery systems inc fisher usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc south san francisco usd spring bioscience corp fremont usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela producto roche caracas vef vietnam roche diagnostic vietnam ltd chi minh city usd share capital local currency unit roche finance report roche group note roche group consolidate financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial report roche finance report report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgement include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche group report statutory auditor consolidated financial statement roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ian starkey franois rouiller basel january roche group report independent auditor internal control financial report roche finance report multiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche group multiyear overview supplementary information roche finance report sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationaddition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information roche finance report core result ep information group basic diluted earning share information give note consolidated financial statement page group expand presentation core result previously core ep show income statement group operating result division show ifrs core basis allow transparent assessment actual result underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring cost note exclude amortisation impairment intangible asset note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental expense financial review exclude global issue outside healthcare sector group control exclude include directly attributable cost earthquake occur japan march note item material onetime treasury item major debt restructuring settlement pension plan currently exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table avoid doublecounting amount show global restructure exclude item operational excellence programme include adjustment column impairment intangible asset total million swiss franc note additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary informationcore result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ global ecp tax ifrs ture sation impairment nation mental issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal sation restruc amorti intangible combi environ ecp tax ifrs ture sation impairment nation mental benefit core sale royalty operating income cost sale marketing distribution research development general administration operate profit associate financial income financing cost profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche group multiyear overview supplementary information roche finance report divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ global ifrs ture sation impairment nation mental issue core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ ifrs ture sation impairment nation mental core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore ep core net income chf million core net income attributable roche shareholder increase noncontrolle interest share core net income assume outstanding chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share core earning share dilute chf roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment intangible asset impairment net assetsheldforsale total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct net cash flow equitysettle equity compensation plan utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision associate current income tax net asset defer income tax net asset postemployment benefit net asset marketable security cash cash equivalent debt net asset net work capital longterm net operating asset total net asset net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision associate current income tax net asset defer income tax net asset postemployment benefit net asset marketable security cash cash equivalent debt net asset net work capital longterm net operating asset total net asset roche group multiyear overview supplementary information roche finance report roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january change ratio adr effective january roche finance report roche group roche securitiesnumber share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number nonvoting equity security genussscheine hold yearend total issue datum share nonvoting equity security chf earning dilute equity attributable roche shareholder dividend stock price share open high low yearend stock price nonvoting equity security genussschein open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche group roche security roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy isk management quity board executive remuneration contingent liability board executive shareholding ignificant shareholder appropriation available earning report statutory auditor financial statement financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year roche holding ltd basel financial statement roche finance report balance sheet million chf december december noncurrent asset participation longterm loan longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value roche finance report roche holding ltd basel financial statementsnotes financial statement summary significant accounting policy basis preparation financial statement financial statement roche holding ltd basel prepare accordance provision swiss law participation major participation company list note roche group consolidate financial statement valuation method translation foreign currency marketable security report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate movement recognise amount millions chf share general legal free special available total capital reserve reserve reserve earnings equity january net income dividend transfer free reserve december net income dividend december net income dividend december roche holding ltd basel note financial statement roche finance report contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc billion swiss franc primarily relate additional bond note issue group company finance genentech transaction guarantee company describe note roche group consolidated financial statement page significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalski hoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri maja oeri jrg duschmal lukas duschmal march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition charitable foundation establish pool member admit pool pool consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder group pool voting right hold share correspond share issue maja oeri member pool hold share represent voting right independently pool december share participation own novartis ltd basel include affiliate thereof information supply shareholder figure share include share pooled voting right hold outside group individual member group information supply shareholder figure share include share pooled voting right hold outside group individual member group figures december supply novartis ltd basel risk management detailed disclosure risk management require swiss law include roche group consolidated financial statement page roche finance report roche holding ltd basel note financial statement board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf gehrig hoffmann baschera bell brabeckletmathe bulcke burns ljr vink franz frey julius levinson oeri ruttenstorfer teltschik voser weder mauro total remuneration board director annual general meeting march frey ruttenstorfer stand reelection annual general meeting march brabeckletmathe teltschik stand reelection annual general meeting march bulcke franz voser elect new member board director remuneration levinson include payment consult work board membership genentech total thousand swiss franc thousand swiss franc chairman board directors franz humer receive remuneration show table remuneration chairman board director thousands chf annual salary include bonus expense bonusspecial stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total roche holding ltd basel note financial statement roche finance report corporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan show table group ceo severin schwan member corporate executive committee high total remuneration remuneration disclose new member corporate executive committee hippe oday soriot include calendar year join cec similarly members corporate executive committee retire way year hunziker include calendar year leave cec remuneration member corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary include bonus expense bonusspecial stock award pension postemployment benefit equity compensation plan retirement awards employee benefit total remuneration receive social security cost total bonusspecial stock award chairman board director member corporate executive committee grant total special stock awards chairman board director receive award members cec receive total award award grant schwan fair value award employee calculate base fair value nonvoting equity security genussscheine grant date chf chf discount account period block year year award bonus member corporate executive committee award form bonus stock awards members cec receive total award award grant schwan fair value award employee calculate base fair value nonvoting equity security genussscheine grant date discount account period block year year employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition award disclose note consolidated financial statement fair value consolidated financial statement represent cost company grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition purpose remuneration disclosure value calculate base fair value employee receive take account preliminary assessment complete performance condition roche finance report roche holding ltd basel notes financial statementsthe chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee swiss franc calculate blackschole formula assume hold maturity deduct average twoyear vest period member corporate executive committee member senior management participate roche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form employee remuneration equal annual amount threeyear cycle award result zero nonvoting equity security genussscheine depend achievement performance target discretion board director individual award relate show table number award calculate follow psp end cycle performance target achieve accordingly participant receive originally target nonvoting equity security genussscheine psp nonvoting equity security genussschein award psp nonvoting equity security genussschein award result allocation multiply nonvoting equity security genussschein price december swiss franc fair value remuneration receive employee remuneration equity compensation plan thousand chf roche connect ssar awards psp award employer ssar ssar psp psp psp psp total contribution number fair value number number number fair value fair value total cec schwan employee benefit include tax advisory cost incidental benefit transaction member corporate executive committee pension tax consulting service total million swiss franc pay group corporate executive committee member million swiss franc member roche holding ltd basel note financial statement roche finance report board executive shareholding board director director andr hoffmann andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine humer gehrig hoffmann baschera bell bulcke burns ljr vink franz frey julius levinson oeri ruttenstorfer voser weder mauro total include share hold shareholder group pool voting right equity compensation award roche option plan ssar roche performance share plan hoffmann oeri hold ubs longshort certificate roche bearer share versus roche nonvoting equity security rog vink hold roche american depositary receipt adr close relative julius hold roche nonvoting equity security genussscheine humer hold rogtpk trackerplus certificate zrcher kantonalbank underlie roche nonvoting equity security rog roche finance report roche holding ltd basel notes financial statementscorporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security genussscheine show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi hippe hunziker keller oday soriot total equity compensation award roche option plan ssar roche performance share plan close relative schwan hold roche nonvoting equity security genussscheine close relative keller hold roche share roche nonvoting equity security genussscheine hippe appoint corporate executive committee effective april hunziker resign corporate executive committee effective march december chairman board director burns members corporate executive committee hold stocksettle stock appreciation right ssar show table award hold humer current chairman board director burns current member board director issue previous capacity member corporate executive committee option entitle holder purchase roche nonvoting equity security genussschein specify strike price term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report include business report annual report page ssar award hold december year issue total schwan ayyoubi hippe keller oday soriot total cec humer burn total strike price chf expiry date feb feb feb jan feb feb soriots award include award strike price chf expire january hippes award strike price chf expire april roche holding ltd basel note financial statement roche finance report december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note consolidated financial statement additional supplementary information remuneration report page business report annual report award result zero non vote equity security genussscheine depend achievement performance target discretion board director end cycle performance target achieve accordingly participant receive originally target nonvoting equity security genussscheine total target number award outstanding cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi hippe keller oday soriot total cec allocation date feb feb december chairman board director burns members corporate executive committee time hold total stocksettle stock appreciation right roche option plan award outstanding total award grant roche performance share plan roche finance report roche holding ltd basel note financial statementsappropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche holding ltd basel appropriation available earning roche finance report report statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany financial statement roche holding ltd comprise income statement balance sheet note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgement include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation roche finance report roche holding ltd basel report statutory auditor financial statementssreport legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche holding ltd basel report statutory auditor financial statement roche finance report publish cautionary statement forwardlooke hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identi fie word believe expect anticipate project intend fax seek estimate future similar expression discussion thing strategy goal plan medium office intention factor cause actual result differ group communication materially future reflect forwardlooke basel switzerland statement contain annual report tel pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring product market fluctuation currency exchange rate general investor relation financial market condition uncertainty discovery basel switzerland development marketing new product new use tel exist product include limitation negative result fax clinical trial research project unexpected effect pipeline market product increase government world wide web pricing pressure interruption production loss wwwrochecom inability obtain adequate protection intellectual property right litigation loss key executive employee adverse publicity news coverage order publication tel statement earning share growth profit fax forecast interpret mean roche email baselwebmasterrochecom earning earning share subsequent period necessarily match exceed historical publish earning annual general meeting earning share roche march trademark mention enjoy legal protection roche finance report publish german english case doubt difference interpretation english version shall prevail german text print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communicationse roche finance report fhoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom